<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravascular brachytherapy for peripheral vascular disease - Andras, A - 2014 | Cochrane Library</title> <meta content="Intravascular brachytherapy for peripheral vascular disease - Andras, A - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003504.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravascular brachytherapy for peripheral vascular disease - Andras, A - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003504.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003504.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intravascular brachytherapy for peripheral vascular disease" name="citation_title"/> <meta content="Alina Andras" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="Monica Hansrani" name="citation_author"/> <meta content="James Cook Hospital" name="citation_author_institution"/> <meta content="Marlene Stewart" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Gerard Stansby" name="citation_author"/> <meta content="Freeman Hospital" name="citation_author_institution"/> <meta content="Gerard.Stansby@nuth.nhs.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD003504.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003504.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003504.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003504.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angioplasty; Brachytherapy [*methods]; Endovascular Procedures [*methods]; Femoral Artery; Peripheral Vascular Diseases [*radiotherapy, therapy]; Popliteal Artery; Quality of Life; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stents; Vascular Patency" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003504.pub2&amp;doi=10.1002/14651858.CD003504.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003504\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003504\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003504.pub2",title:"Intravascular brachytherapy for peripheral vascular disease",firstPublishedDate:"Jan 8, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003504.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003504.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003504.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003504.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003504.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003504.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003504.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003504.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003504.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003504.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1177 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003504.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-sec1-0006"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-sec1-0001"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-sec1-0002"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-sec1-0003"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-sec1-0004"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-sec1-0005"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/appendices#CD003504-sec1-0011"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/table_n/CD003504StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/table_n/CD003504StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravascular brachytherapy for peripheral vascular disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#CD003504-cr-0002">Alina Andras</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#CD003504-cr-0003">Monica Hansrani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#CD003504-cr-0004">Marlene Stewart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information#CD003504-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Gerard Stansby</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information/en#CD003504-sec1-0015">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003504.pub2">https://doi.org/10.1002/14651858.CD003504.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003504-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003504-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003504-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003504-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003504-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003504-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003504-abs-0001" lang="en"> <section id="CD003504-abs1-0001"> <h3 class="title" id="CD003504-abs1-0001">Background</h3> <p>Interventional treatment of arteries that are narrowed and obstructed by atherosclerosis involves either bypassing the blockage using a graft; widening the artery from the inside with a balloon, a procedure known as percutaneous transluminal angioplasty (PTA); or providing a strut to hold the vessel open, known as a stent. All of these treatments are, however, limited by the high numbers that fail within a year. Intravascular brachytherapy is the application of radiation directly to the site of vessel narrowing. It is known to inhibit the processes that lead to restenosis (narrowing) of vessels and grafts after treatment. This is an update of a review first published in 2002. </p> </section> <section id="CD003504-abs1-0002"> <h3 class="title" id="CD003504-abs1-0002">Objectives</h3> <p>To assess the efficacy of, and complications associated with, intravascular brachytherapy (IVBT) for maintaining patency after angioplasty or stent insertion in native vessels or bypass grafts of the iliac or infrainguinal arteries. </p> </section> <section id="CD003504-abs1-0003"> <h3 class="title" id="CD003504-abs1-0003">Search methods</h3> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched their Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). </p> </section> <section id="CD003504-abs1-0004"> <h3 class="title" id="CD003504-abs1-0004">Selection criteria</h3> <p>Randomised controlled trials of the use of brachytherapy as an adjunct to the endovascular treatment of people with peripheral arterial disease (PAD) or stenosed bypass grafts of the iliac or infrainguinal arteries versus the procedure without brachytherapy. </p> </section> <section id="CD003504-abs1-0005"> <h3 class="title" id="CD003504-abs1-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and two other review authors independently extracted the data. Adverse event information was collected from the trials. </p> </section> <section id="CD003504-abs1-0006"> <h3 class="title" id="CD003504-abs1-0006">Main results</h3> <p>Eight trials with a combined total of 1090 participants were included in this review. All included studies used the femoropopliteal artery. We did not identify any studies that used the iliac arteries. All studies compared PTA with or without stenting plus IVBT versus PTA with or without stenting alone. No trials were found comparing IVBT to technologies such as drug eluting stents or balloons, or cryoplasty. Follow‐up ranged from six months to five years. The quality of the included trials was moderate with our concerns relating to the difficulty of blinding due to the nature of the procedures and the small sample sizes for some studies. Primary outcomes (patency or restenosis and need for re‐intervention) were reported in the majority of the trials, but reporting at various time points and the use of multiple definitions of the outcomes by the included studies meant that not all data were available for pooling. The secondary outcomes were not reported in many of the included studies. </p> <p>For brachytherapy, cumulative patency was higher at 24 months (odds ratio (OR) 2.36, 95% confidence interval (CI) 1.36 to 4.10, n = 222, P = 0.002). A statistically significant difference was found for restenosis at six months (OR 0.27, 95% CI 0.11 to 0.66, n = 562, P = 0.004), 12 months (OR 0.44, 95% CI 0.28 to 0.68, n = 375, P = 0.0002) and 24 months (OR 0.41, 95% CI 0.21 to 0.78, n = 164, P = 0.007) in favour of IVBT. No difference was found after five years as measured in one study. The need for re‐interventions was reported in six studies. Target lesion revascularisation was significantly reduced in trial participants treated with IVBT compared with angioplasty alone (OR 0.51, 95% CI 0.27 to 0.97, P = 0.04) at six months after the interventions. No statistically significant difference was found between the procedures on the need for re‐intervention at 12 and 24 months after the procedures. </p> <p>A statistically significant lower number of occlusions was found in the control group at more than three months (OR 11.46, 95% CI 1.44 to 90.96, n = 363, P = 0.02) but no differences were found at less than one month nor at 12 months after the procedures making the clinical significance uncertain. Ankle brachial index was statistically significantly better for IVBT at the 12 month follow‐up (mean difference 0.08, 95% CI 0.02 to 0.14, n = 100, P = 0.02) but no statistically significant differences were found at 24 hours and at six months. </p> <p>Quality of life, complications, limb loss, cardiovascular deaths, death from all causes, pain free walking distance and maximum walking distance on a treadmill were similar for the two arms of the trials with no statistically significant difference found between the treatment groups. </p> </section> <section id="CD003504-abs1-0007"> <h3 class="title" id="CD003504-abs1-0007">Authors' conclusions</h3> <p>The evidence for using peripheral artery brachytherapy as an adjunct to percutaneous transluminal angioplasty to maintain patency and for the prevention of restenosis in people with peripheral vascular disease is limited, mainly due to the inconsistency of assessment and reporting of clinically relevant outcomes. More data are needed on clinically relevant outcomes such as health related quality of life (HRQOL) or limb salvage and longer‐term outcomes, together with comparisons with other techniques such as drug eluting balloons and stents. Adequately powered randomised controlled trials, health economics and cost‐effectiveness data are required before the procedure could be recommended for widespread use. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003504-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003504-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003504-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003504-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003504-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003504-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003504-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003504-abs-0006" lang="en"> <h3>Intravascular brachytherapy (radiation treatment), inside arteries or bypass grafts, after angioplasty or stent surgery </h3> <p>Intravascular brachytherapy (radiation treatment) inside arteries after angioplasty, stent insertion, or bypass grafts may prevent narrowing of the arteries or grafts. Narrowed and blocked arteries can be treated by bypassing the blockage using a graft, angioplasty (widening the artery by inserting a balloon), or inserting a stent (thin metal sleeve) to hold the artery open. However, restenosis (return of the narrowing or obstruction) often occurs within a year. Intravascular brachytherapy (IVBT) aims to prevent restenosis by the application of radiation to the affected part of the artery after the angioplasty or stent insertion. </p> <p>This review included eight studies with a total of 1090 participants. All eight included studies used the femoropopliteal artery. We did not identify any studies that used the iliac arteries. All trials compared angioplasty with or without stenting plus IVBT with angioplasty with or without stenting alone. No trials were found comparing IVBT to newer technologies such as drug eluting stents, balloons, or cryoplasty. Intravascular brachytherapy resulted in increased cumulative patency, reduced restenosis, and fewer occlusions on short‐term follow‐ups. However, results from the eight included trials were not consistent and long‐term outcomes need to be fully assessed. Therefore, more research is needed especially regarding the long‐term outcomes and complications of this treatment, and the health economics and cost‐effectiveness data. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003504-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003504-sec1-0006"></div> <h3 class="title" id="CD003504-sec1-0007">Implications for practice</h3> <section id="CD003504-sec1-0007"> <p>The evidence for using peripheral artery brachytherapy as an adjunct to percutaneous transluminal angioplasty in maintaining patency and for the prevention of restenosis and other clinically relevant outcomes such as health related quality of life (HRQOL) and limb salvage in people with peripheral vascular disease is limited, mainly due to the inconsistencies of assessment and reporting of clinically relevant outcomes. In particular, more data on long‐term outcomes and comparisons with other techniques such as drug eluting balloons and stents, together with health economics and cost‐effectiveness data, are required before the procedure could be recommended for widespread use. </p> </section> <h3 class="title" id="CD003504-sec1-0008">Implications for research</h3> <section id="CD003504-sec1-0008"> <p>Longer‐term follow‐up in currently running and future trials is essential if the potential short and long‐term complications and durability of this adjuvant therapy are to be properly evaluated. Future studies should aim to apply standardised outcomes and have complete reporting of findings. Angioplasty with adjuvant brachytherapy can be extended to other sites such as renal or carotid arteries. Brachytherapy should be studied with other technologies such as drug eluting balloons and drug eluting stents. HRQOL should be included and it will allow more detailed cost‐effectiveness analyses to be done. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003504-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003504-sec1-0001"></div> <section id="CD003504-sec2-0001"> <h3 class="title" id="CD003504-sec2-0001">Description of the condition</h3> <p>In the UK and US, symptomatic peripheral arterial disease (PAD) occurs in 4.5% to 7% of people over the age of 55 years (<a href="./references#CD003504-bbs2-0036" title="DewhurstG , WoodDA , WalkerF , LampeFC , JeffreysM , CooperM , et al. A population survey of cardiovascular disease in elderly people: design, methods and prevalence results. Age and Ageing1991;20(5):353‐60. ">Dewhurst 1991</a>; <a href="./references#CD003504-bbs2-0042" title="FowkesFG , HousleyE , CawoodEH , MacintyreCC , RuckleyCV , PrescottRJ . Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral vascular disease in the general population. International Journal of Epidemiology1991;20(2):384‐92. ">Fowkes 1991</a>; <a href="./references#CD003504-bbs2-0082" title="SelvinE , ErlingerTP . Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999 ‐ 2000. Circulation2004;110(6):738‐43. ">Selvin 2004</a>). In 25% of these patients, the condition will deteriorate and require treatment but fewer than 5% will go on to develop limb threatening critical limb ischaemia (CLI) (<a href="./references#CD003504-bbs2-0039" title="DormandyJA , MurrayGD . The fate of the claudicant‐‐a prospective study of 1969 claudicants. European Journal of Vascular Surgery1991;5(2):131‐3. ">Dormandy 1991</a>). CLI is diagnosed only in 1% to 2% of all patients with PAD at the initial presentation (<a href="./references#CD003504-bbs2-0050" title="HirschAT , HaskalZJ , HertzerNR , BakalCW , CreagerMA , HalperinJL , et al. ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)‐summary of recommendations. Circulation2006;113(11):e463‐654. ">Hirsch 2006</a>). More than 50% of those who require treatment will be suitable candidates for endovascular methods of intervention (<a href="./references#CD003504-bbs2-0058" title="LondonNJ , VartyK , SayersRD , ThompsonMM , BellPR , BoliaA . Percutaneous transluminal angioplasty for lower‐limb critical ischaemia. British Journal of Surgery1995;82(9):1232‐5. ">London 1995</a>) and patients with CLI have a 50% risk of major amputation if they do not undergo revascularisation (<a href="./references#CD003504-bbs2-0050" title="HirschAT , HaskalZJ , HertzerNR , BakalCW , CreagerMA , HalperinJL , et al. ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)‐summary of recommendations. Circulation2006;113(11):e463‐654. ">Hirsch 2006</a>). Patients with PAD have a shorter life expectancy due to the coexistence of other cardiovascular disorders (<a href="./references#CD003504-bbs2-0085" title="StansbyG , MisterR , FowkesG , RoughtonM , NugaraF , BrittendenJ , et al. High risk of peripheral arterial disease in the United Kingdom: 2‐year results of a prospective registry. Angiology2011;62(2):111‐8. ">Stansby 2011</a>). </p> <p>A Cochrane review of trials (which included only 98 participants in total) suggested that although angioplasty may be of short‐term benefit, this may not be sustained in the long‐term (<a href="./references#CD003504-bbs2-0043" title="FowkesFG , GillespieIN . Angioplasty (versus non surgical management) for intermittent claudication. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000017] ">Fowkes 2006</a>). Narrowing of the artery following angioplasty (restenosis) is the major cause of long‐term failure. Restenosis is caused by three processes, immediate elastic recoil of the vessel, myointimal hyperplasia (enlargement of the inner muscular layer of vessels), and late vascular remodelling (changes in the vessel, produced in response to physical stresses on the vessel wall, which affect the shape and volume of the vessel). The addition of acute thrombosis can lead to complete occlusion (obstruction or complete blockage) of a restenosed vessel. </p> </section> <section id="CD003504-sec2-0002"> <h3 class="title" id="CD003504-sec2-0002">Description of the intervention</h3> <p>Percutaneous balloon angioplasty is a technique for restoring blood flow through an artery that has become narrowed or blocked by atherosclerosis. A small balloon is inserted into the artery and inflated, thus rupturing the atheromatous plaque, stretching the smooth muscle cells within the middle of the vessel and widening the arterial lumen. Angioplasty is particularly effective in the iliac vessels, but the technique is also successful for treating femoropopliteal arteries. Two year patency rates for femoropopliteal disease is around 80% (<a href="./references#CD003504-bbs2-0025" title="Agency for Healthcare Research and Quality. Treatment strategies for patients with peripheral artery disease. Effective health care programme. Comparative effectiveness review number 118. http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1517/peripheral‐artery‐disease‐treatment‐report‐130525.pdf2013. ">AHRQ 2013</a>). Five year patency rates for iliac and femoropopliteal angioplasty are 50% to 60% and 52% respectively (<a href="./references#CD003504-bbs2-0024" title="AdarR , CritchfieldGC , EddyDM . A confidence profile analysis of the results of femoropopliteal percutaneous transluminal angioplasty in the treatment of lower extremity ischaemia. Journal of Vascular Surgery1989;10(1):57‐67. ">Adar 1989</a>; <a href="./references#CD003504-bbs2-0053" title="KudoT , ChandraFA , AhnSS . Long‐term outcomes and predictors of iliac angioplasty with selective stenting. Journal of Vascular Surgery2005;42(3):466‐75. ">Kudo 2005</a>; <a href="./references#CD003504-bbs2-0054" title="KudoT , ChandraFA , KwunWH , HaasBT , AhnSS . Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. Journal of Vascular Surgery2006;44(2):304‐13. ">Kudo 2006</a>; <a href="./references#CD003504-bbs2-0056" title="LeuAJ , SchneidnerE , CanovaCR , HoffmanU . Long‐term results after recanalisation of chronic iliac artery occlusions by combined catheter therapy without stent placement. European Journal of Vascular and Endovascular Surgery1999;18(6):499‐505. ">Leu 1999</a>; <a href="./references#CD003504-bbs2-0059" title="LongAL , PagePE , RaynaudAC , BeyssenBM , FiessingerJN , DucimetiereP , et al. Percutaneous iliac artery stent: angiographic long‐term follow‐up. Radiology1991;180(3):771‐8. ">Long 1991</a>; <a href="./references#CD003504-bbs2-0061" title="MartinEC , KatzenBT , BenenatiJF , DiethrichEB , DorrosG , GraorRA , et al. Multicenter trial of the wall stent in the iliac and femoral arteries. Journal of Vascular and Interventional Radiology1995;6(6):843‐9. ">Martin 1995</a>; <a href="./references#CD003504-bbs2-0066" title="MurphyKD , EncarnacionCE , LeVA , PalmazJC . Iliac artery stent placement with the Palmaz stent: follow‐up study. Journal of Vascular and Interventional Radiology1995;6(3):321‐9. ">Murphy 1995</a>; <a href="./references#CD003504-bbs2-0074" title="RutherfordRB , DurhamJD . Percutaneous balloon angioplasty for arteriosclerosis obliterans: long‐term results. In: YoaJST , PearceW editor(s). Technologies in vascular surgery. Philadelphia: WB Saunders, 1991:329‐45. ">Rutherford 1991</a>; <a href="./references#CD003504-bbs2-0075" title="RutherfordRB , DurhamJD , KumpeDA . Endovascular intervention for lower extremity ischemia. In: RutherfordRB editor(s). Vascular Surgery ‐ IV edition. Orlando: WB Saunders, 1995:858‐74. ">Rutherford 1995</a>). More recent studies suggest a five year patency rate in the iliac artery of around 80% (<a href="./references#CD003504-bbs2-0057" title="LevilleCD , KashyapVS , ClairDG , BenaJF , LydenSP , GreenbergRK , et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter‐Society Consensus class C and D patients. Journal of Vascular Surgery2006;43(1):32‐9. ">Leville 2006</a>; <a href="./references#CD003504-bbs2-0068" title="ParkKB , DoYS , KimJH , HanYH , KimDI , KimDK , et al. Stent placement for chronic iliac arterial occlusive disease:the results of 10 years experience in a single institution. Korean Journal of Radiology2005;6(4):256‐66. ">Park 2005</a>; <a href="./references#CD003504-bbs2-0069" title="ParkKB , DoYS , KimDI , KimDK , KimYW , ShinSW , et al. The TransAtlantic InterSociety Consensus (TASC) classification system in iliac arterial stent placement: long‐term patency and clinical limitations. Journal of Vascular and Interventional Radiology2007;18(2):193‐201. ">Park 2007</a>). </p> <p>An important cause of failure after angioplasty is myointimal hyperplasia, which is the unrestricted migration and proliferation of vascular smooth muscle cells into the vessel lumen leading to narrowing of the vessel and restriction of blood flow. The stimulus for this cellular migration is unclear and therapeutic approaches are being sought to regulate this process (<a href="./references#CD003504-bbs2-0030" title="ClowesAW , ReidyMA , ClowesMM . Mechanisms of stenosis after arterial injury. Laboratory Investigation1983;49(2):208‐15. ">Clowes 1983</a>; <a href="./references#CD003504-bbs2-0038" title="DilleyRJ , McGeachieJK , PrendergastFJ . A review of the histologic changes in vein‐to‐artery grafts, with particular reference to intimal hyperplasia. Archives of Surgery1988;123(6):691‐6. ">Dilley 1988</a>; <a href="./references#CD003504-bbs2-0063" title="MintzGS , PopmaJJ , PichardAD , KentKM , SatlerLF , WongC , et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation1996;94(1):35‐43. ">Mintz 1996</a>; <a href="./references#CD003504-bbs2-0084" title="SottiuraiVS , YaoJS , FlinnWR , BatsonRC . Intimal hyperplasia and neointima: An ultrastructural analysis of thrombosed grafts in humans. Surgery1983;93(6):809‐17. ">Sottiurai 1983</a>). Myofibroblasts of the adventitia also contribute to the process of vascular lesion formation (<a href="./references#CD003504-bbs2-0080" title="ScottNA , CipollaGD , RossCE , DunnB , MartinFH , SimonetL , et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation1996;93(12):2178‐87. ">Scott 1996</a>; <a href="./references#CD003504-bbs2-0081" title="ScottNA , WilcoxJN . The role of adventitial vasculature in restenosis: a new view of an old problem. Journal of the American College of Cardiology1998;32(7):2080. ">Scott 1998</a>). </p> <p>Intravascular brachytherapy (IVBT) is a technique that is intended to suppress cellular proliferation and migration by directing radiation at the site of the vascular intervention. IVBT is based on the concept that proliferating smooth muscle cells and myofibroblasts are more sensitive to the effects of low doses of radiation than non‐proliferating cells (<a href="./references#CD003504-bbs2-0046" title="HallE . Radiobiology for the radiologists. 4th Edition. Philadelphia: JB Lippincott Company, 1994. ">Hall 1994</a>; <a href="./references#CD003504-bbs2-0102" title="WilcoxJN , WaksmanR , KingSB , ScottNA . The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. International Journal of Radiation Oncology, Biology, Physics1996;36(4):789‐96. ">Wilcox 1996</a>). It allows a localised delivery of radiation to inhibit the proliferative response seen after angioplasty (<a href="./references#CD003504-bbs2-0035" title="DaviesMG , Anaya‐AyalaJE . Endovascular techniques in limb salvage: cutting, cryo, brachy, and drug‐eluting balloons. Methodist Debakey Cardiovascular Journal2013;9(2):69‐72. ">Davies 2013</a>; <a href="./references#CD003504-bbs2-0095" title="WaksmanR , RodriguezJC , RobinsonKA , CipollaGD , CrockerIR , ScottNA , et al. Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation1997;96(6):1944‐52. ">Waksman 1997</a>). </p> </section> <section id="CD003504-sec2-0003"> <h3 class="title" id="CD003504-sec2-0003">How the intervention might work</h3> <p>Although two forms of radiation are commonly used for IVBT (gamma and beta), both have limitations when used in peripheral vessels (<a href="./references#CD003504-bbs2-0028" title="BertrandOF , MongrainR , LehnertS , BilodeauL , TanguayJF , LaurierJ , et al. Intravascular radiation therapy in atherosclerotic disease: promises and premises. European Heart Journal1997;18(9):1385‐95. ">Bertrand 1997</a>). Beta sources produce high‐energy particle radiation which rapidly loses activity over short distances of the vessel wall. This limited penetration means that in order to guarantee that the entire arterial wall receives an equal dose, particularly with larger peripheral vessels, it is essential that the radiation source be centred in the lumen of the vessel. By comparison, electromagnetic gamma‐radiation penetrates well beyond the vessel wall, thus removing the degree of precision that is required with beta‐radiation. However, this increased penetration increases the risk of potential damage to surrounding tissues and, therefore, increases the oncogenic (cancer causing) potential of the intervention. Gamma‐radiation also requires more elaborate and costly radiation protection measures for the operators. Both types of radiation can be delivered by either intravascular insertion of a catheter containing the radiation source in a balloon (beads, gel, liquid) or a wire source where the tip of the wire is radioactive. These sources are placed in the target vessel for a calculated period of time to deliver the required dose (<a href="./references#CD003504-bbs2-0067" title="NathR , AmolsH , CoffeyC , DugganD , JaniS , LiZ , et al. Intravascular brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group no.60. American Association of Physicists in Medicine. Medical Physics1999;26(2):119‐52. ">Nath 1999</a>). Alternative methods for delivering the radiation involve the insertion of a permanent low‐activity radioactive stent with a radioactive half‐life tailored to the purpose, for example phosphorus‐32, with vanadium‐48 and yttrium‐90 considered as alternatives (<a href="./references#CD003504-bbs2-0041" title="FeresF , MuñozJS , AbizaidA , AlbertalM , MintzGS , StaicoR , et al. Comparison between sirolimus‐eluting stents and intracoronary catheter‐based beta radiation for the treatment of in‐stent restenosis. American Journal of Cardiology2005;96(12):1656‐62. ">Feres 2005</a>; <a href="./references#CD003504-bbs2-0047" title="HanefeldC , AmirieS , BorchardtD , GreweP , MüllerKM , KisslerM , et al. Dosimetric measurements in isolated human coronary arteries: comparison of commercially available iridium(192) with strontium/yttrium(90) emitters. Circulation2002;105(21):2493‐6. ">Hanefeld 2002</a>; <a href="./references#CD003504-bbs2-0073" title="RoratE , PetelenzB , MarczewskaB , OchabE . Thermoluminescence dosimetry of model line sources containing vanadium‐48. Radiation Measurements2005;39(5):495‐501. ">Rorat 2005</a>). </p> <p>Extensive work on animals has confirmed the inhibition of acute and late restenosis by IVBT and, more importantly, reported a low incidence of adverse effects (<a href="./references#CD003504-bbs2-0048" title="HehrleinC , StintzM , KinscherfR , SchlösserK , HuttelE , FriedrichL , et al. Pure beta‐particle‐emitting stents inhibit neointima formation in rabbits. Circulation1996;93(4):641‐5. ">Hehrlein 1996</a>; <a href="./references#CD003504-bbs2-0089" title="VerinV , PopowskiY , UrbanP , BelengerJ , RedardM , CostaM , et al. Intra‐arterial beta irradiation prevents neointimal hyperplasia in a hypercholesterolemic rabbit restenosis model. Circulation1995;92(8):2284‐90. ">Verin 1995</a>; <a href="./references#CD003504-bbs2-0093" title="WaksmanR , RobinsonKA , CrockerIR , GravanisMB , CipollaGD , KingSB3rd . Endovascular low‐dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation1995;91(5):1533‐9. ">Waksman 1995a</a>; <a href="./references#CD003504-bbs2-0094" title="WaksmanR , RobinsonKA , CrockerIR , WangC , GravanisMB , CipollaGD , et al. Intracoronary low‐dose beta‐irradiation inhibits neointima formation after coronary artery balloon injury in the swine restenosis model. Circulation1995;92(10):3025‐31. ">Waksman 1995b</a>; <a href="./references#CD003504-bbs2-0100" title="WeinbergerJ , AmolsH , EnnisRD , SchwartzA , WiedermannJG , MarboeC . Intracoronary irradiation: dose response for the prevention of restenosis in swine. International Journal of Radiation Oncology, Biology, Physics1996;36(4):767‐75. ">Weinberger 1996</a>; <a href="./references#CD003504-bbs2-0101" title="WiedermannJG , MarboeC , AmolsH , SchwartzA , WeinbergerJ . Intracoronary irradiation markedly reduces restenosis after balloon angioplasty in a porcine model. Journal of the American College of Cardiology1994;23(6):1491‐8. ">Wiedermann 1994</a>) thereby providing the impetus for human trials. Much of our understanding of IVBT has been gathered from studies of radiotherapy in coronary arteries. Published trials in coronary arteries have been uniformly optimistic. The first published trial of coronary artery IVBT was by Condado et al (<a href="./references#CD003504-bbs2-0031" title="CondadoJ , GurdielO , EspinozaR , BritoJG , HarrisonML , JoynerLR , et al. Percutaneous transluminal coronary angioplasty (PTCA) and intracoronary radiation therapy (ICRT): a possible new modality for the treatment of coronary restenosis: a preliminary report of the first 10 patients treated with intracoronary radiation therapy. Journal of the American College of Cardiology1995;25(2s1):288A. ">Condado 1995</a>) in Venezuela who treated 21 participants with gamma‐irradiation after balloon angioplasty. Although two participants had immediate failures, none of the 19 remaining participants showed evidence of late occlusion at the two year angiographic follow‐up (<a href="./references#CD003504-bbs2-0033" title="CondadoJA , WaksmanR , CalderasC , SaucedoJ , LanskyA . Two‐year follow‐up after intracoronary gamma radiation therapy. Cardiovascular Radiation Medicine1999;1(1):30‐5. ">Condado 1999</a>). The Coronary Radiation to Inhibit Proliferation Post Stenting (SCRIPPS) study showed similarly impressive results (<a href="./references#CD003504-bbs2-0087" title="TeirsteinPS , MassulloV , JaniS , PopmaJJ , MintzGS , RussoRJ , et al. Catheter‐based radiotherapy to inhibit restenosis after coronary stenting. New England Journal of Medicine1997;336(24):1697‐703. ">Teirstein 1997</a>). At three years, restenosis was nearly twice as common in the control group as in the brachytherapy group (64% versus 33%) (<a href="./references#CD003504-bbs2-0088" title="TeirsteinPS , MassulloV , JaniS , PopmaJJ , RussoRJ , SchatzRA , et al. Three‐year clinical and angiographic follow‐up after intracoronary radiation: results of a randomized clinical trial. Circulation2000;101(4):360‐5. ">Teirsten 2000</a>), a trend reproduced by several subsequent trials (<a href="./references#CD003504-bbs2-0052" title="KingSB3rd , WilliamsDO , ChouguleP , KleinJL , WaksmanR , HilsteadR , et al. Endovascular beta‐radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT). Circulation1998;97(20):2025‐30. ">King 1998</a>; <a href="./references#CD003504-bbs2-0055" title="LeonMB , TeirsteinPS , MosesJW , TripuraneniP , LanskyAJ , JaniS , et al. Localized intracoronary gamma‐radiation therapy to inhibit the recurrence of restenosis after stenting. New England Journal of Medicine2001;344(4):250‐6. ">Leon 2001</a>; <a href="./references#CD003504-bbs2-0064" title="MintzGS , WeissmanNJ , TeirsteinPS , EllisSG , WaksmanR , RussoRJ , et al. Effect of intracoronary gamma‐radiation therapy on in‐stent restenosis: An intravascular ultrasound analysis from the gamma‐1 study. Circulation2000;102(24):2915‐8. ">Mintz 2000</a>; <a href="./references#CD003504-bbs2-0090" title="VerinV , PopowskiY , deBruyneB , BaumgartD , SauerweinW , LinsM , et al. for the Dose‐Finding Study Group. Endoluminal beta‐radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose‐Finding Study Group. New England Journal of Medicine2001;344(4):243‐9. ">Verin 2001</a>; <a href="./references#CD003504-bbs2-0096" title="WaksmanR . Intracoronary radiation therapy for restenosis prevention: status of the clinical trials. Cardiovascular Radiation Medicine1999;1(1):20‐9. ">Waksman 1999a</a>; <a href="./references#CD003504-bbs2-0098" title="WaksmanR , WhiteRL , ChanRC , BassBG , GeirlachL , MintzGS , et al. Intracoronary gamma‐radiation therapy after angioplasty inhibits recurrence in patients with in‐stent restenosis. Circulation2000;101(18):2165‐71. ">Waksman 2000a</a>). IVBT has also been shown to have a profound effect on vascular remodelling in coronary arteries. Studies have demonstrated increases in initial luminal volume of almost 50% in arteries treated with gamma or beta‐radiation (<a href="./references#CD003504-bbs2-0032" title="CondadoJA , WaksmanR , GurdielO , EspinosaR , GonzalezJ , BurgerB , et al. Long‐term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation1997;96(3):727‐32. ">Condado 1997</a>; <a href="./references#CD003504-bbs2-0076" title="SabateM , SerruysPW , van derGiessenWJ , LigthartJM , CoenVL , KayIP , et al. Geometric vascular remodeling after balloon angioplasty and beta‐radiation therapy: A three‐dimensional intravascular ultrasound study. Circulation1999;100(11):1182‐8. ">Sabate 1999</a>). </p> <p>Although the initial benefits of IVBT appear to be very promising, the long‐term consequences remain unknown. For example, the longest running trial has published results that follow‐up participants for only eight years (<a href="./references#CD003504-bbs2-0012" title="LiermannD , KirchnerJ , BauernsachsR , SchopohlB , BottcherHD . Brachytherapy with iridium‐192 HDR to prevent from restenosis in peripheral arteries. An update. Herz1998;23(6):394‐400. ">Liermann 1998</a>). No evidence of clinical nerve damage or local malignancy has been observed. However, early trials in coronary IVBT exposed a high incidence of late thrombosis, approaching 6.2% to 6.6%, in participants treated with IVBT (control participants showed an incidence of 0.7% to 0.8%) and this was significantly higher in participants who underwent simultaneous stent insertion (<a href="./references#CD003504-bbs2-0034" title="CostaMA , SabatéM , van derGiessenWJ , KayIP , CervinkaP , LigthartJM , et al. Late coronary occlusion after intracoronary brachytherapy. Circulation1999;100(8):789‐92. ">Costa 1999</a>; <a href="./references#CD003504-bbs2-0055" title="LeonMB , TeirsteinPS , MosesJW , TripuraneniP , LanskyAJ , JaniS , et al. Localized intracoronary gamma‐radiation therapy to inhibit the recurrence of restenosis after stenting. New England Journal of Medicine2001;344(4):250‐6. ">Leon 2001</a>; <a href="./references#CD003504-bbs2-0088" title="TeirsteinPS , MassulloV , JaniS , PopmaJJ , RussoRJ , SchatzRA , et al. Three‐year clinical and angiographic follow‐up after intracoronary radiation: results of a randomized clinical trial. Circulation2000;101(4):360‐5. ">Teirsten 2000</a>; <a href="./references#CD003504-bbs2-0099" title="WaksmanR , BhargavaB , LeonMB . Late thrombosis following intracoronary brachytherapy. Catheterization and Cardiovascular Interventions2000;49(3):344‐7. ">Waksman 2000b</a>). Treatment with radioactivity delays re‐endothelisation of inserted stents and may induce endothelial dysfunction causing arterial spasm (<a href="./references#CD003504-bbs2-0028" title="BertrandOF , MongrainR , LehnertS , BilodeauL , TanguayJF , LaurierJ , et al. Intravascular radiation therapy in atherosclerotic disease: promises and premises. European Heart Journal1997;18(9):1385‐95. ">Bertrand 1997</a>; <a href="./references#CD003504-bbs2-0091" title="VirmaniR , FarbA . Assessing the advantages and disadvantages of novel radiation therapy for vascular restenosis: injury score, artery size, and short lengths. Cardiovascular Radiation Medicine1999;1(3):308‐10. ">Virmani 1999</a>). High dose radiation is also known to induce thrombosis, perhaps by increasing platelet activation whilst inhibiting mechanisms involved in resolution (the physiological process by which the body repairs itself to become as close to the normal state as possible) (<a href="./references#CD003504-bbs2-0077" title="SalameM , LampkinJ , MulkeySP , CuiJ , VerheyeS , HillsteadRA , et al. Effects of endovascular irradiation on platelet recruitment at sites of balloon angioplasty in pig coronary arteries. Journal of the American College of Cardiology1999;33:44A Abstract No. 1070‐60. ">Salame 1999</a>; <a href="./references#CD003504-bbs2-0092" title="VodovotzY , WaksmanR , KimWH , BhargavaB , ChanRC , LeonM . Effects of intracoronary radiation on thrombosis following balloon overstretch injury in the porcine model. Circulation1999;100(25):2527‐33. ">Vodovotz 2001</a>; <a href="./references#CD003504-bbs2-0097" title="WaksmanR . Late thrombosis after radiation. Sitting on a time bomb. Circulation1999;100(8):780‐2. ">Waksman 1999b</a>). The US Federal Drug Agency (FDA) reviewed data from several trials in relation to this complication (<a href="./references#CD003504-bbs2-0078" title="SapirsteinW , ZuckermanB , DillardJ . FDA approval of coronary‐artery brachytherapy. New England Journal of Medicine2001;344(4):297‐9. ">Sapirstein 2001</a>) and concluded that the high incidence in early studies was caused by premature cessation of antiplatelet therapy. Sapirstein et al recommended the avoidance of IVBT with simultaneous stent insertion and suggested the maintenance of antiplatelet therapy for a minimum of six months after IVBT and for one year if a new stent was implanted simultaneously (<a href="./references#CD003504-bbs2-0078" title="SapirsteinW , ZuckermanB , DillardJ . FDA approval of coronary‐artery brachytherapy. New England Journal of Medicine2001;344(4):297‐9. ">Sapirstein 2001</a>). In general, all patients with PAD should be permanently on antiplatelet therapy unless contraindicated (<a href="./references#CD003504-bbs2-0060" title="MannavaK , MoneySR . Current management of peripheral arterial occlusive disease: a review of pharmacologic agents and other interventions. American Journal of Cardiovascular Drugs2007;7(1):59‐66. ">Mannava 2007</a>). </p> <p>Fibrosis of irradiated vessels may weaken vessel walls, while initially favourable adaptive remodelling could lead to late aneurysm formation (<a href="./references#CD003504-bbs2-0032" title="CondadoJA , WaksmanR , GurdielO , EspinosaR , GonzalezJ , BurgerB , et al. Long‐term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation1997;96(3):727‐32. ">Condado 1997</a>; <a href="./references#CD003504-bbs2-0076" title="SabateM , SerruysPW , van derGiessenWJ , LigthartJM , CoenVL , KayIP , et al. Geometric vascular remodeling after balloon angioplasty and beta‐radiation therapy: A three‐dimensional intravascular ultrasound study. Circulation1999;100(11):1182‐8. ">Sabate 1999</a>). The combined effect of these processes could be exacerbated by asymmetric centring of the radiation source during IVBT, which could lead to some areas of the wall receiving a much higher dose of radiation than others. </p> <p>There is also evidence that low dose radiation could stimulate myointimal hyperplasia (proliferation of cells into the innermost layer of vessels, particularly at the edges of stents. This leads to a characteristic luminal narrowing phenomenon known as the 'candy‐wrapper' or edge effect (<a href="./references#CD003504-bbs2-0026" title="AlbieroR , NishidaT , AdamianM , AmatoA , VaghettiM , CorvajaN , et al. Edge restenosis after implantation of high activity (32)P radioactive beta‐emitting stents. Circulation2000;101(21):2454‐7. ">Albiero 2000</a>; <a href="./references#CD003504-bbs2-0040" title="EisingEG , WienekeH . Is there a relation between 'candy wrapper,' prevention of (for instance) coronary artery disease, and therapy of postdiscectomy syndrome by irradiation?. Cardiovascular Radiation Medicine2001;2(2):104‐6. ">Eising 2001</a>). The luminal narrowing phenomenon can be reduced in coronary arteries by using a longer brachytherapy source (<a href="./references#CD003504-bbs2-0027" title="BaggaR , KiniA , LeeP , AgarwalA , DuffyM , KimM , et al. Intracoronary brachytherapy for in‐stent restenosis using long sources reduces restenosis. Journal of Invasive Cardiology2005;17(6):302‐6. ">Bagga 2005</a>). In vitro experiments showed that beta‐radiation treatment can alter the reactivity of certain proteins of the vessel wall extracellular matrix and the vessel wall becomes less prone to platelet adhesion resulting in a decrease of thrombus formation (<a href="./references#CD003504-bbs2-0105" title="WuYP , StellaPR , ChenSF , WangYT , WangJY , MoerlandMA , et al. β‐radiation reduces the reactivity of extracellular matrix proteins in intravascular brachytherapy (IVBT), resulting in decreased platelet adhesion. International Journal of Cardiology2012;156(3):283‐8. ">Wu 2012</a>). </p> </section> <section id="CD003504-sec2-0004"> <h3 class="title" id="CD003504-sec2-0004">Why it is important to do this review</h3> <p>Many questions about this technique remain unanswered at this stage, including the safety, efficacy and the cost‐effectiveness of the brachytherapy. This meta‐analysis of available trial data aims to evaluate the technique and would help direct further research into IVBT. This is an update of a review first published in 2002 (<a href="./references#CD003504-bbs2-0108" title="HansraniM , OverbeckK , SmoutJJ , StansbyGP . Intravascular brachytherapy for peripheral vascular disease. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD003504] ">Hansrani 2002</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003504-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003504-sec1-0002"></div> <p>To assess the efficacy of, and complications associated with, intravascular brachytherapy (IVBT) for maintaining patency after angioplasty or stent insertion in native vessels or bypass grafts of the iliac or infrainguinal arteries. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003504-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003504-sec1-0003"></div> <section id="CD003504-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003504-sec3-0001"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) in which people with peripheral arterial disease (PAD), or stenosed bypass grafts, of the iliac or infrainguinal arteries were randomised to brachytherapy with or without another procedure versus a procedure without brachytherapy. </p> </section> <section id="CD003504-sec3-0002"> <h4 class="title">Types of participants</h4> <p>Males and females of any age diagnosed with PAD by an expert clinician through clinical and investigative assessment (ankle brachial pressure index, duplex, exercise testing or angiography) and who required vascular intervention that could be appropriately managed with IVBT and were deemed fit to undergo such an intervention. </p> </section> <section id="CD003504-sec3-0003"> <h4 class="title">Types of interventions</h4> <p>Trials including any form of therapy that involved the use of brachytherapy applied intravascularly for the treatment of PAD were considered for inclusion. Trials were divided into subgroups according to the radioactive source (beta or gamma, and radioactive isotope) used; accompanying procedure (angioplasty, stent insertion, thrombectomy, etc.); short‐term (catheter based) or long‐term (radioactive stents) brachytherapy; total dosage and dosage profile; indication for intervention (CLI, intermittent claudication); and de novo or repeat procedure. Additional therapies, in particular the adjuvant use of antiplatelet or anticoagulant agents, were also assessed. </p> </section> <section id="CD003504-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD003504-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p>The following primary outcome measures were considered:</p> <p> <ul id="CD003504-lst1-0001"> <li> <p>primary patency or restenosis;</p> </li> <li> <p>need for re‐intervention (including target lesion revascularisation and target vessel revascularisation). </p> </li> </ul> </p> <p>Clinical patency is defined as sustained clinical success without further intervention, whilst cumulative patency is defined as the percentage of lesions which have &lt; 50% restenosis with or without further intervention during the follow‐up period. Restenosis is the narrowing of a blood vessel after it has been opened, usually by balloon angioplasty. It is defined as ≥ 50% luminal diameter stenosis. </p> <p>Re‐intervention is indicated in symptomatic restenosis or reocclusions post‐intervention either in the treated segment (target lesion revascularisation (TLR)) or secondary to progression of the disease in non‐treated segments of the vessel (target vessel revascularisation (TVR)). </p> </section> <section id="CD003504-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p>The following secondary outcome measures were considered:</p> <p> <ul id="CD003504-lst1-0002"> <li> <p>occlusion;</p> </li> <li> <p>immediate success of procedure (within 30 days);</p> </li> <li> <p>limb loss or amputation free survival;</p> </li> <li> <p>cardiovascular death (i.e. death from any atherogenic cause, cerebrovascular accident, myocardial infarction, aneurysm, etc., including death during surgery for these conditions); </p> </li> <li> <p>death from all causes;</p> </li> <li> <p>complications (e.g. early thrombosis, aneurysm formation, nerve damage, malignancy, lesions secondary to use of radiation); </p> </li> <li> <p>bleeding;</p> </li> <li> <p>ankle brachial index (the highest systolic pressure at the ankle compared to the highest of the right or left brachial systolic pressures) (ABI); </p> </li> <li> <p>pain free walking distance;</p> </li> <li> <p>maximum walking distance on treadmill;</p> </li> <li> <p>quality of life.</p> </li> </ul> </p> <p>Cost‐effectiveness in terms of morbidity and mortality and use of resources (for example bed days) was also considered if the information was provided. </p> </section> </section> </section> <section id="CD003504-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003504-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator (TSC) searched their Specialised Register (last searched August 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 7), part of <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). See <a href="./appendices#CD003504-sec2-0016">Appendix 1</a> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Peripheral Vascular Diseases (PVD) Group module in <i>The Cochrane Library</i> (<a href="http://www.thecochranelibrary.com" target="_blank">www.thecochranelibrary.com</a>). </p> </section> <section id="CD003504-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>The reference lists of relevant articles retrieved as a result of the electronic searches were searched for additional citations. </p> </section> </section> <section id="CD003504-sec2-0007"> <h3 class="title" id="CD003504-sec2-0007">Data collection and analysis</h3> <section id="CD003504-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>The selection of trials for inclusion in the review was carried out by two review authors (MH, GS). All disagreements were successfully resolved by consensus. </p> </section> <section id="CD003504-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>Data collection was carried out in duplicate by two review authors (AA, MS) to ensure quality control and included information on participants (age and sex distribution, measures of severity of disease such as ABI), interventions and doses (element used, method of treatment) and outcomes (as above). All disagreements were successfully resolved by consensus. </p> </section> <section id="CD003504-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The methodological quality of each trial was assessed independently by two review authors (MH, GS). The risk of bias in the included studies was assessed using the Cochrane Collaboration's tool for assessing risk of bias (<a href="./references#CD003504-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic reviews of Interventions Version 5.1.0 [updated March 2011]. Wiley‐Blackwell, 2011. ">Higgins 2011</a>). This includes the domains of sequence generation; allocation concealment; blinding of participants, personnel and assessors; inappropriate outcome data; selective outcome reporting; and other sources of bias. The domains were judged to be either at 'low risk', 'high risk' or 'unclear risk' of bias according to <a href="./references#CD003504-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic reviews of Interventions Version 5.1.0 [updated March 2011]. Wiley‐Blackwell, 2011. ">Higgins 2011</a>. </p> </section> <section id="CD003504-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5.2, provided by The Cochrane Collaboration, to analyse the data. For dichotomous outcomes, the statistical analysis was presented as odds ratio (OR) with 95% confidence interval (CI). We used mean differences (MD) with 95% CI for continuous outcomes. </p> </section> <section id="CD003504-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>Participating individuals in each RCT were the unit of analysis.</p> </section> <section id="CD003504-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>Multiple attempts were made to contact study authors to clarify data. One of the three study authors who were contacted responded to our request for data. Data that remained missing or unclear were not included in the analyses. </p> </section> <section id="CD003504-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>We based all analyses on the intention‐to‐treat data from individual trials. We assessed trial heterogeneity using the I<sup>2</sup> statistic. Where heterogeneity was identified (I<sup>2</sup> &gt; 50%), we investigated the reason for heterogeneity. If no apparent reason was found, we conducted a random‐effects model meta‐analysis. In the absence of heterogeneity we used a fixed‐effect model meta‐analysis. </p> </section> <section id="CD003504-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use asymmetry in funnel plots to assess reporting bias. However, due to the small number of included trials, this was not performed as the power of analysis would have been too low to distinguish chance from real asymmetry (<a href="./references#CD003504-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic reviews of Interventions Version 5.1.0 [updated March 2011]. Wiley‐Blackwell, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD003504-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model meta‐analysis where clinical and statistical heterogeneity existed (I<sup>2</sup> &gt; 50%). We used a fixed‐effect model meta‐analysis in the absence of heterogeneity. </p> </section> <section id="CD003504-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses where possible, including subgroup analyses for participants with grafts as opposed to participants being treated for native vessel disease, type and length of lesion, de novo or repeat procedures, the accompanying procedure (angioplasty, stent insertion, thrombectomy, etc.) and indication for intervention (CLI, intermittent claudication). We also planned to perform subgroup analysis for participants with vessels or grafts requiring re‐intervention (with stratification for time from implantation to re‐intervention), the radioactive source (beta or gamma‐radiation, and radioactive isotope), total dosage and dosage profile, and short‐term (catheter based) or long‐term (radioactive stents) brachytherapy if sufficient data were available. </p> </section> <section id="CD003504-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses based on the risk of bias if there were studies with high risk of bias (that is, with high risk methods of allocation concealment and random sequence generation) included in the analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003504-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003504-sec1-0004"></div> <section id="CD003504-sec2-0008"> <h3 class="title">Description of studies</h3> <p>For a detailed description of studies see <a href="./references#CD003504-sec2-0019" title="">Characteristics of included studies</a> and <a href="./references#CD003504-sec2-0020" title="">Characteristics of excluded studies</a>. </p> <section id="CD003504-sec3-0018"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD003504-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003504-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003504-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>For this update we identified seven additional included studies following screening of the CENTRAL and PVD Specialised Register search results. A further 10 additional studies were excluded. </p> </section> <section id="CD003504-sec3-0019"> <h4 class="title">Included studies</h4> <p>One study (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) had been included in the original version of the review and an additional seven studies were included in this update (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>). The eight included studies involved a total of 1090 participants (<a href="#CD003504-tbl-0002">Table 1</a>). All included studies used the femoropopliteal artery. All included studies compared PTA with or without stenting plus IVBT with PTA with or without stenting alone. No trials were found comparing IVBT to other technologies such as drug eluting stents, balloons, or cryoplasty. </p> <div class="table" id="CD003504-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusions/</p> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Complications</p> <p>(documented)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age (y)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> <p>(n)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean lesion length ‐</p> <p>control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean lesion length ‐</p> <p>treated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (51 ‐ 73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 ± 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71 (45 ‐ 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 + 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 (43 ‐ 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71 (43 ‐ 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (50 ‐ 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>y: years<br/> n: number </p> </div> </div> <p>In terms of primary outcome events, seven trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) reported patency or restenosis and six trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) reported technical success or need for re‐intervention at various time points. </p> <p>In terms of secondary outcome events, the following information was reported:</p> <p> <ul id="CD003504-lst1-0003"> <li> <p>occlusion was reported in five studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); </p> </li> <li> <p>immediate success of the procedure was reported by all eight studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); </p> </li> <li> <p>limb loss was reported by one trial (<a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>); </p> </li> <li> <p>cardiovascular death was reported at different time points by three trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>); </p> </li> <li> <p>death from all causes was reported at different time points by seven trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); </p> </li> <li> <p>complications were reported by six trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); </p> </li> <li> <p>bleeding was reported by one study (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>); </p> </li> <li> <p>ABI was reported at different time points by four trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); </p> </li> <li> <p>pain free walking distance was reported at one time point by one trial (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>); </p> </li> <li> <p>maximum walking distance on a treadmill was reported at different time points by two trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); </p> </li> <li> <p>quality of life was reported by one trial (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>). </p> </li> </ul> </p> <p><a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a> randomised 30 participants with de novo stenoses or occlusions resulting in claudication to PTA alone or PTA + 14 gray (Gy) from a centred iridium‐192 (Ir‐192) source. No participants were stented. All participants were treated with aspirin 100 mg daily and heparin peri‐procedure. The primary endpoint was restenosis at 12 months. Follow‐up to 24 months has also been reported. </p> <p>The <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> (Probucol And Brachytherapy) trial in Switzerland recruited 335 participants in a 2 x 2 factorial design into four groups: PTA alone, PTA + 14 Gy non‐centred Ir‐192, PTA + probucol, and PTA + probucol + 14 Gy non‐centred Ir‐192. Stenting was allowed and only claudicants with de novo femoropopliteal stenoses and occlusions were recruited. All participants received aspirin 100 mg daily and those in whom stents were placed received clopidogrel 75 mg daily. The primary endpoint was restenosis at six month follow‐up. Twenty participants from the trial were used in an analysis of the effect of IVBT on vascular lumen dimensions as measured by magnetic resonance imaging (MRI) at three and 24 months (<a href="./references#CD003504-bbs2-0106" title="WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">Wyttenbach 2004</a>; <a href="./references#CD003504-bbs2-0107" title="WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34:416‐23. ">Wyttenbach 2007</a>). A subgroup analysis of those participants in whom stents were placed was carried out to assess the effect of IVBT in addition to stenting on late thrombotic occlusions (<a href="./references#CD003504-bbs2-0029" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. ">Bonvini 2003</a>). <a href="./references#CD003504-bbs2-0037" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ">Diehm 2005</a> pooled participants from the <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> and <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trials to perform a subgroup analysis looking at recurrent versus de novo lesions and stenoses versus occlusions. </p> <p>The only US based RCT was the Peripheral Artery Radiation Investigational Study (<a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>), which was completed in 2002. Two hundred and three participants were enrolled to undergo PTA alone or PTA with 14 Gy from a centred Ir‐192 source. Although the trial group published their initial feasibility study results (<a href="./references#CD003504-bbs2-0015" title="WaksmanR , LairdJR , JurkovitzCT , LanskyAJ , GerritsF , KosinskiAS , et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. Journal of Vascular and Interventional Radiology2001;12(8):915‐21. ">PARIS I</a>), disappointingly they have not published the results from the completed RCT. Preliminary results from follow‐up of 75 of the participants were presented at the 2003 Annual Transcatheter Cardiovascular Therapeutics meeting. </p> <p>The <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trial recruited 100 participants with recurrent stenoses or occlusions of the femoropopliteal vessels resulting in claudication or CLI. The participants were randomised to PTA with or without stenting and with or without 12 Gy from a non‐centred Ir‐192 source. Information on antithrombotic or anticoagulant therapy was not provided. The primary endpoint was restenosis at 12 months follow‐up. </p> <p>The <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> (VAscular RAdiation) trial from the Netherlands was a multicentre (eight centres) RCT initiated in 1998 where participants with de novo stenoses or occlusions were randomised prior to undergoing initial PTA to receiving IVBT or not. Because of the protocol, 17 participants were excluded immediately leaving 60 participants, 33 controls treated with PTA with and without stenting and 27 treated with additional 14 Gy centred Ir‐192. Participants with both claudication and CLI were included. All participants were treated with aspirin 100 mg daily long‐term. The primary endpoint was restenosis rate at 12 months follow‐up. <a href="./references#CD003504-bbs2-0045" title="HagenaarsT , A Po IF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. ">Hagenaars 2002</a> analysed a subgroup of 24 trial participants to assess vascular lumen dimensions as measured by duplex ultrasound. </p> <p>After successfully conducting an initial feasibility study to assess the safety and efficacy of IVBT, in 10 participants with long segment restenosis who underwent non‐centred 12 Gy IVBT without complications (<a href="./references#CD003504-bbs2-0019" title="MinarE , PokrajacB , AhmadiR , MacaT , SeitzW , StumpflenA , et al. Brachytherapy for prophylaxis of restenosis after long‐segment femoropopliteal angioplasty: pilot study. Radiology1998;208(1):173‐9. ">Vienna 1</a>), the Vienna group started recruiting in 1996 for the <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> trial in which 113 participants were randomised after PTA to receiving IVBT 12 Gy by a non‐centred Ir source or not. Included were de novo and recurrent lesions, both stenoses &gt; 5 cm and occlusions. Participants with claudication and CLI were allowed. All participants received aspirin 100 mg/day (from at least two weeks prior to the procedure and continued indefinitely post‐procedure) and heparin therapy for 24 hours peri‐procedure. The primary endpoint was angiographic patency at six months. Secondary outcomes included restenosis rates, revascularisation rates, ABI and peak velocity ratios (ratio of peak systolic velocity within the stenosis to peak systolic velocity just prior to the stenosis) as determined by duplex measurements (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>). The group have published an update of the trial with 102 participants completing five year follow‐up (<a href="./references#CD003504-bbs2-0104" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. ">Wolfram 2006a</a>). Using a subgroup of 34 participants from this study, <a href="./references#CD003504-bbs2-0070" title="PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. ">Pokrajac 2002a</a> looked at the potential effect of using a non‐centred source on restenosis. Trials run by this group following <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> used a centred source. A very small randomised single centre study performed in 2000 in Salzburg (<a href="./references#CD003504-bbs2-0051" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. ">Hofmann 2002</a>) (part of <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) randomised nine participants with de novo or recurrent lesions of the femoropopliteal vessels to 18 Gy centred Ir‐192, or not, post‐PTA (<a href="./references#CD003504-bbs2-0051" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. ">Hofmann 2002</a>). All participants were treated with aspirin 100 mg daily and heparin peri‐procedure. The focus of the publication was on thrombotic sequelae of the procedure. This was an analysis of a subset of participants from a single centre participating in a multicentre trial (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>). </p> <p>In the <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> multicentre trial in 1998, 134 participants with de novo or recurrent stenoses or occlusions of the femoropopliteal vessels were randomised to receiving PTA with or without 18 Gy via a centred Ir‐192 source. Participants requiring stenting were excluded but both claudicants and participants with CLI were included. All participants were treated with aspirin 100 mg daily and heparin. The primary endpoint of the study was arterial patency at 12 months follow‐up. A subgroup analysis was performed to assess de novo versus recurrent lesions from participants enrolled in the Vienna 2 and 3 trials (<a href="./references#CD003504-bbs2-0103" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Wolfram 2005</a>). </p> <p>The Vienna 4 trial was a non‐randomised feasibility study of 33 participants (<a href="./references#CD003504-bbs2-0020" title="WolframRM , PokrajacB , AhmadiR , FellnerC , GyongyosiM , HaumerM , et al. Endovascular brachytherapy for prophylaxis against restenosis after long‐segment femoropopliteal placement of stents: initial results. Radiology2001;220(3):724‐9. ">Vienna 4</a>), which was performed prior to enrolment started for the double‐blind multicentre <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> trial. Ninety‐four participants were enrolled with de novo or recurrent stenoses or occlusions of the femoropopliteal vessels. All participants underwent PTA and stenting with Wallstent or nitinol stents prior to randomisation to receiving additional 14 Gy from a centred Ir‐192 source or not (control). The primary endpoint was restenosis at six months follow‐up. All participants were treated with dual aspirin 100 mg and clopidogrel 75 mg daily therapy and peri‐procedural heparin treatment. <a href="./references#CD003504-bbs2-0079" title="SchillingerM , MlekuschW , WolframRM , BudinskyAC , ExnerM , RumpoldH , et al. Endovascular brachytherapy: effect on acute inflammatory response after percutaneous femoropopliteal arterial interventions. Radiology2004;230(2):556‐60. ">Schillinger 2004</a> assessed the effect of IVBT and stenting on acute phase proteins in a small subset of participants from the <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> and <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> trials. </p> </section> <section id="CD003504-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>See the table <a href="./references#CD003504-sec2-0020" title="">Characteristics of excluded studies</a>. </p> <p>In total, 15 studies (<a href="./references#CD003504-bbs2-0009" title="BoselliG , BenincasaA , LoG , CasaliG , TusiniN , VecchiatiE , et al. Percutaneous transluminal angioplasty stent implantation and intravascular high dose rate brachytherapy in femoro‐popliteal arteries. Giornale Italiano di Chirurgia Vascolare2002;9(4):347‐55. ">Boselli 2002</a>; <a href="./references#CD003504-bbs2-0010" title="BottcherHD , SchopohlB , LiermannD , KollathJ , AdamietzIA . Endovascular irradiation‐‐a new method to avoid recurrent stenosis after stent implantation in peripheral arteries: technique and preliminary results. International Journal of Radiation Oncology, Biology, Physics1994;29(1):183‐6. ">Bottcher 1994</a>; <a href="./references#CD003504-bbs2-0011" title="KrugerK , BendelM , ZahringerM , BongartzR , NolteM , SchulteO , et al. Endovascular gamma‐irradiation for prevention of restenosis after angioplasty of femoropopliteal denovo stenoses; long term results of a feasibility study. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin2002;174(3):321‐7. ">Kruger 2002</a>; <a href="./references#CD003504-bbs2-0012" title="LiermannD , KirchnerJ , BauernsachsR , SchopohlB , BottcherHD . Brachytherapy with iridium‐192 HDR to prevent from restenosis in peripheral arteries. An update. Herz1998;23(6):394‐400. ">Liermann 1998</a>; <a href="./references#CD003504-bbs2-0013" title="Novoste . The LIMBER trial (Limb ischemia treatment and monitoring post vascular brachytherapy to prevent restenosis). ">LIMBER</a>; <a href="./references#CD003504-bbs2-0014" title="Novoste . Corona system. Patient guide and information leaflet. http://www.bestvascular.com/assets/Beta‐Cath%203.5F%20%205F%20Systems%20Dose%20Equivalency.pdf (accessed 22 May 2013). ">MOBILE</a>; <a href="./references#CD003504-bbs2-0015" title="WaksmanR , LairdJR , JurkovitzCT , LanskyAJ , GerritsF , KosinskiAS , et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. Journal of Vascular and Interventional Radiology2001;12(8):915‐21. ">PARIS I</a>; <a href="./references#CD003504-bbs2-0016" title="PichlerLJ , HawliczekR , SomloiA , MayrhoferR , SchmidtWF , HrubyW . Endovascular brachytherapy for the prevention of recurrence after PTA. Der Radiologe1999;39(2):118‐24. ">Pichler 1999</a>; <a href="./references#CD003504-bbs2-0017" title="PokrajacB , KirisitsC , SchmidR , SchillingerM , BergerD , PeerK , et al. Beta endovascular brachytherapy using CO2‐filled centering catheter for treatment of recurrent superficial femoropopliteal artery disease. Cardiovascular Revascularization Medicine2009;10(3):162‐5. ">Pokrajac 2009</a>; <a href="./references#CD003504-bbs2-0018" title="SchopohlB , LeirmannD , PohlitLJ , HeydR , StrassmannG , BauersachsR , et al. 192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. International Journal of Radiation Oncology, Biology, Physics1996;36(4):835‐40. ">Schopohl 1996</a>; <a href="./references#CD003504-bbs2-0019" title="MinarE , PokrajacB , AhmadiR , MacaT , SeitzW , StumpflenA , et al. Brachytherapy for prophylaxis of restenosis after long‐segment femoropopliteal angioplasty: pilot study. Radiology1998;208(1):173‐9. ">Vienna 1</a>; <a href="./references#CD003504-bbs2-0020" title="WolframRM , PokrajacB , AhmadiR , FellnerC , GyongyosiM , HaumerM , et al. Endovascular brachytherapy for prophylaxis against restenosis after long‐segment femoropopliteal placement of stents: initial results. Radiology2001;220(3):724‐9. ">Vienna 4</a>; <a href="./references#CD003504-bbs2-0021" title="WalichiewiczP , PiecuchJ , BialasB , OrkiszW , FijalkowskiM , MiszczykL . Vascular brachytherapy after percutaneous transluminal angioplasty of superficial femoral arteries‐Polish pilot group. Cardiovascular Radiation Medicine2002;3(1):2‐6. ">Walichiewicz 2002</a>; <a href="./references#CD003504-bbs2-0022" title="WalichiewiczP , PiecuchJ , BialasB , OrkiszW , FijalkowskiM , SlosarekK , et al. Endovascular gamma irradiation of the iliac arteries: 1 year results from a clinical safety and feasibility study. Journal of Endovascular TherapyJun 2003;10(3):573‐6. ">Walichiewicz 2003</a>; <a href="./references#CD003504-bbs2-0023" title="WernerM , ScheinertD , HennM , ScheinertS , BräunlichS , BausbackY , et al. Endovascular brachytherapy using liquid Beta‐emitting rhenium‐188 for the treatment of long‐segment femoropopliteal in‐stent stenosis. Journal of Endovascular Therapy2012;19(4):467‐75. ">Werner 2012</a>) were excluded. Thirteen studies were excluded because they were non‐randomised studies (<a href="./references#CD003504-bbs2-0009" title="BoselliG , BenincasaA , LoG , CasaliG , TusiniN , VecchiatiE , et al. Percutaneous transluminal angioplasty stent implantation and intravascular high dose rate brachytherapy in femoro‐popliteal arteries. Giornale Italiano di Chirurgia Vascolare2002;9(4):347‐55. ">Boselli 2002</a>; <a href="./references#CD003504-bbs2-0010" title="BottcherHD , SchopohlB , LiermannD , KollathJ , AdamietzIA . Endovascular irradiation‐‐a new method to avoid recurrent stenosis after stent implantation in peripheral arteries: technique and preliminary results. International Journal of Radiation Oncology, Biology, Physics1994;29(1):183‐6. ">Bottcher 1994</a>; <a href="./references#CD003504-bbs2-0011" title="KrugerK , BendelM , ZahringerM , BongartzR , NolteM , SchulteO , et al. Endovascular gamma‐irradiation for prevention of restenosis after angioplasty of femoropopliteal denovo stenoses; long term results of a feasibility study. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin2002;174(3):321‐7. ">Kruger 2002</a>; <a href="./references#CD003504-bbs2-0012" title="LiermannD , KirchnerJ , BauernsachsR , SchopohlB , BottcherHD . Brachytherapy with iridium‐192 HDR to prevent from restenosis in peripheral arteries. An update. Herz1998;23(6):394‐400. ">Liermann 1998</a>; <a href="./references#CD003504-bbs2-0015" title="WaksmanR , LairdJR , JurkovitzCT , LanskyAJ , GerritsF , KosinskiAS , et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. Journal of Vascular and Interventional Radiology2001;12(8):915‐21. ">PARIS I</a>; <a href="./references#CD003504-bbs2-0016" title="PichlerLJ , HawliczekR , SomloiA , MayrhoferR , SchmidtWF , HrubyW . Endovascular brachytherapy for the prevention of recurrence after PTA. Der Radiologe1999;39(2):118‐24. ">Pichler 1999</a>; <a href="./references#CD003504-bbs2-0017" title="PokrajacB , KirisitsC , SchmidR , SchillingerM , BergerD , PeerK , et al. Beta endovascular brachytherapy using CO2‐filled centering catheter for treatment of recurrent superficial femoropopliteal artery disease. Cardiovascular Revascularization Medicine2009;10(3):162‐5. ">Pokrajac 2009</a>; <a href="./references#CD003504-bbs2-0018" title="SchopohlB , LeirmannD , PohlitLJ , HeydR , StrassmannG , BauersachsR , et al. 192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. International Journal of Radiation Oncology, Biology, Physics1996;36(4):835‐40. ">Schopohl 1996</a>; <a href="./references#CD003504-bbs2-0019" title="MinarE , PokrajacB , AhmadiR , MacaT , SeitzW , StumpflenA , et al. Brachytherapy for prophylaxis of restenosis after long‐segment femoropopliteal angioplasty: pilot study. Radiology1998;208(1):173‐9. ">Vienna 1</a>; <a href="./references#CD003504-bbs2-0020" title="WolframRM , PokrajacB , AhmadiR , FellnerC , GyongyosiM , HaumerM , et al. Endovascular brachytherapy for prophylaxis against restenosis after long‐segment femoropopliteal placement of stents: initial results. Radiology2001;220(3):724‐9. ">Vienna 4</a>; <a href="./references#CD003504-bbs2-0021" title="WalichiewiczP , PiecuchJ , BialasB , OrkiszW , FijalkowskiM , MiszczykL . Vascular brachytherapy after percutaneous transluminal angioplasty of superficial femoral arteries‐Polish pilot group. Cardiovascular Radiation Medicine2002;3(1):2‐6. ">Walichiewicz 2002</a>; <a href="./references#CD003504-bbs2-0022" title="WalichiewiczP , PiecuchJ , BialasB , OrkiszW , FijalkowskiM , SlosarekK , et al. Endovascular gamma irradiation of the iliac arteries: 1 year results from a clinical safety and feasibility study. Journal of Endovascular TherapyJun 2003;10(3):573‐6. ">Walichiewicz 2003</a>; <a href="./references#CD003504-bbs2-0023" title="WernerM , ScheinertD , HennM , ScheinertS , BräunlichS , BausbackY , et al. Endovascular brachytherapy using liquid Beta‐emitting rhenium‐188 for the treatment of long‐segment femoropopliteal in‐stent stenosis. Journal of Endovascular Therapy2012;19(4):467‐75. ">Werner 2012</a>), including the very first publication of the therapeutic use of brachytherapy in PAD (<a href="./references#CD003504-bbs2-0010" title="BottcherHD , SchopohlB , LiermannD , KollathJ , AdamietzIA . Endovascular irradiation‐‐a new method to avoid recurrent stenosis after stent implantation in peripheral arteries: technique and preliminary results. International Journal of Radiation Oncology, Biology, Physics1994;29(1):183‐6. ">Bottcher 1994</a>). None of these pilot or feasibility studies used a control group and they had very small numbers of participants (10 to 45 participants). </p> <p><a href="./references#CD003504-bbs2-0010" title="BottcherHD , SchopohlB , LiermannD , KollathJ , AdamietzIA . Endovascular irradiation‐‐a new method to avoid recurrent stenosis after stent implantation in peripheral arteries: technique and preliminary results. International Journal of Radiation Oncology, Biology, Physics1994;29(1):183‐6. ">Bottcher 1994</a> published his findings on the use of a non‐centred Ir‐192 gamma source to deliver 12 Gy IVBT to restenoses or reocclusions in the superficial femoral artery (SFA) of 13 participants. All participants were stented and the IVBT was performed without incident. They reported that all treated vessels remained patent at three to 27 months follow‐up. </p> <p><a href="./references#CD003504-bbs2-0012" title="LiermannD , KirchnerJ , BauernsachsR , SchopohlB , BottcherHD . Brachytherapy with iridium‐192 HDR to prevent from restenosis in peripheral arteries. An update. Herz1998;23(6):394‐400. ">Liermann 1998</a> reported the outcomes of 40 participants (a previous publication reported on 28 of these participants (<a href="./references#CD003504-bbs2-0018" title="SchopohlB , LeirmannD , PohlitLJ , HeydR , StrassmannG , BauersachsR , et al. 192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. International Journal of Radiation Oncology, Biology, Physics1996;36(4):835‐40. ">Schopohl 1996</a>)) treated with 12 Gy from a non‐centred Ir‐192 source for recurrent stenoses or occlusions of the previously treated SFA segments, with a follow‐up period of four months to 7.5 years. They reported freedom from restenosis in 33 of the 40 participants; one participant developed acute thrombosis at three months and another developed restenosis at 12 months. Pichler's group (<a href="./references#CD003504-bbs2-0016" title="PichlerLJ , HawliczekR , SomloiA , MayrhoferR , SchmidtWF , HrubyW . Endovascular brachytherapy for the prevention of recurrence after PTA. Der Radiologe1999;39(2):118‐24. ">Pichler 1999</a>) successfully treated 24 de novo and recurrent lesions in the SFA segment with 14 Gy non‐centred Ir‐192. At 15 months they reported cumulative patency rates of 60%, with no major adverse events. Similarly <a href="./references#CD003504-bbs2-0009" title="BoselliG , BenincasaA , LoG , CasaliG , TusiniN , VecchiatiE , et al. Percutaneous transluminal angioplasty stent implantation and intravascular high dose rate brachytherapy in femoro‐popliteal arteries. Giornale Italiano di Chirurgia Vascolare2002;9(4):347‐55. ">Boselli 2002</a> treated the stented SFA segments of 45 participants with non‐centred Ir‐192. They reported immediate patency rates of 95%, with a 12 month patency of 80%. </p> <p><a href="./references#CD003504-bbs2-0011" title="KrugerK , BendelM , ZahringerM , BongartzR , NolteM , SchulteO , et al. Endovascular gamma‐irradiation for prevention of restenosis after angioplasty of femoropopliteal denovo stenoses; long term results of a feasibility study. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin2002;174(3):321‐7. ">Kruger 2002</a> performed non‐centred IVBT using a Ir‐192 source to deliver 12 Gy in six participants with de novo SFA stenoses and gave one participant centred IVBT. They reported restenosis in only one of the seven participants, with follow‐up out to four years. Walichiewicz also reported the results of their pilot study, in 2002 (<a href="./references#CD003504-bbs2-0021" title="WalichiewiczP , PiecuchJ , BialasB , OrkiszW , FijalkowskiM , MiszczykL . Vascular brachytherapy after percutaneous transluminal angioplasty of superficial femoral arteries‐Polish pilot group. Cardiovascular Radiation Medicine2002;3(1):2‐6. ">Walichiewicz 2002</a>). They treated 20 limbs of 19 participants with 15 Gy Ir‐192 applied to de novo stenoses or occlusions of the SFA, with follow‐up of one to 14 months. All participants underwent angiographic assessment at follow‐up. At six months the trialists observed four (20%) acute thrombotic occlusions and no restenoses, and recommended six months of aggressive antiplatelet therapy with ticlopidine in participants who had stents in situ. </p> <p>Waksman (<a href="./references#CD003504-bbs2-0015" title="WaksmanR , LairdJR , JurkovitzCT , LanskyAJ , GerritsF , KosinskiAS , et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. Journal of Vascular and Interventional Radiology2001;12(8):915‐21. ">PARIS I</a>) reported the results of their feasibility pilot study, called PARIS 1, in 2001. They recruited 40 participants with claudication to undergo PTA to their SFA followed by 14 Gy delivered by a centred, specially designed afterloader, with follow‐up at six months. The procedure was unsuccessful in five (12.5%) of their cases; two participants dropped out due to complications of PTA and in three the catheter kinked and would not allow passage of the radiation source. Two participants died and four refused angiographic follow‐up before the initial assessment at six months. At six month angiographic follow‐up the restenosis rate was 17.2% (6/35 participants) and three required revascularisation. At 12 months follow‐up the clinical restenosis rate was 13.3% (in 30 participants). </p> <p>The Vienna group published their initial feasibility study, Vienna 1, looking at 10 participants treated with PTA followed by 12 Gy IVBT from a non‐centred Ir‐192 source to de novo long SFA restenoses (<a href="./references#CD003504-bbs2-0019" title="MinarE , PokrajacB , AhmadiR , MacaT , SeitzW , StumpflenA , et al. Brachytherapy for prophylaxis of restenosis after long‐segment femoropopliteal angioplasty: pilot study. Radiology1998;208(1):173‐9. ">Vienna 1</a>). The procedure was performed with complications in all participants. At 12 months follow‐up they reported a restenosis rate of 40%, with no reocclusions. <a href="./references#CD003504-bbs2-0020" title="WolframRM , PokrajacB , AhmadiR , FellnerC , GyongyosiM , HaumerM , et al. Endovascular brachytherapy for prophylaxis against restenosis after long‐segment femoropopliteal placement of stents: initial results. Radiology2001;220(3):724‐9. ">Vienna 4</a> reported the results of their second pilot study, Vienna 4, which was designed specifically to include PTA + stenting of the femoropopliteal segment with IVBT using a centred catheter to deliver 14 Gy. Thirty‐three participants were successfully treated with no initial adverse events. Restenosis at six months occurred in 30%, with seven participants developing late thrombotic occlusions. </p> <p><a href="./references#CD003504-bbs2-0017" title="PokrajacB , KirisitsC , SchmidR , SchillingerM , BergerD , PeerK , et al. Beta endovascular brachytherapy using CO2‐filled centering catheter for treatment of recurrent superficial femoropopliteal artery disease. Cardiovascular Revascularization Medicine2009;10(3):162‐5. ">Pokrajac 2009</a> published a case series using a beta source, strontium‐90, for performing IVBT with a CO<sub>2</sub>‐filling centring balloon to treat 28 participants with either recurrent SFA stenoses or in‐stent restenoses, providing 14 to 18 Gy. There were no adverse events and all procedures were successful, with two participants requiring stenting. Reported restenosis rates were 9% at one year, 28% at two years and 40% at three years, with target vessel revascularisation performed in 25%. </p> <p>In the only reported study of IVBT to the iliac arteries, <a href="./references#CD003504-bbs2-0022" title="WalichiewiczP , PiecuchJ , BialasB , OrkiszW , FijalkowskiM , SlosarekK , et al. Endovascular gamma irradiation of the iliac arteries: 1 year results from a clinical safety and feasibility study. Journal of Endovascular TherapyJun 2003;10(3):573‐6. ">Walichiewicz 2003</a> reported on 14 participants (15 arteries) treated with PTA with or without stenting and 15 Gy from a centred Ir‐192 source. All participants received six months of antiplatelet therapy (ticlopidine) post‐procedure. All procedures were successful and at six months the study authors reported one (6.7%) angiographically proven restenosis and one participant with transient limb ischaemia. </p> <p><a href="./references#CD003504-bbs2-0023" title="WernerM , ScheinertD , HennM , ScheinertS , BräunlichS , BausbackY , et al. Endovascular brachytherapy using liquid Beta‐emitting rhenium‐188 for the treatment of long‐segment femoropopliteal in‐stent stenosis. Journal of Endovascular Therapy2012;19(4):467‐75. ">Werner 2012</a> reported on a non‐randomised study evaluating 90 consecutive participants undergoing angioplasty and subsequent endovascular brachytherapy using a dose of 13 Gy at a depth of 2 mm into the vessel wall. Follow‐up data continued for up to two years. All procedures were successful in all participants, with one early stent thrombosis but no other complications related to the irradiation. Primary patency was 95.2% and 79.8% at six and 12 months, respectively. The clinical status improved in 67.0% and 62.2% of the participants after six and 12 months, respectively. </p> <p><a href="./references#CD003504-bbs2-0013" title="Novoste . The LIMBER trial (Limb ischemia treatment and monitoring post vascular brachytherapy to prevent restenosis). ">LIMBER</a> and <a href="./references#CD003504-bbs2-0014" title="Novoste . Corona system. Patient guide and information leaflet. http://www.bestvascular.com/assets/Beta‐Cath%203.5F%20%205F%20Systems%20Dose%20Equivalency.pdf (accessed 22 May 2013). ">MOBILE</a> were excluded because they were halted and the results never published. <a href="./references#CD003504-bbs2-0013" title="Novoste . The LIMBER trial (Limb ischemia treatment and monitoring post vascular brachytherapy to prevent restenosis). ">LIMBER</a> aimed to recruit 25 participants who would undergo PTA + IVBT with a 32P beta source applied to femoropopliteal segment lesions, whilst <a href="./references#CD003504-bbs2-0014" title="Novoste . Corona system. Patient guide and information leaflet. http://www.bestvascular.com/assets/Beta‐Cath%203.5F%20%205F%20Systems%20Dose%20Equivalency.pdf (accessed 22 May 2013). ">MOBILE</a> aimed to perform a RCT of 400 participants from the US and Europe with in‐stent restenosis of the femoropopliteal segment, with a lesion length of 4 to 30 cm, comparing PTA + stent versus PTA + stent + IVBT using a 32P beta source. </p> </section> </section> <section id="CD003504-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003504-fig-0002">Figure 2</a>; <a href="#CD003504-fig-0003">Figure 3</a> for graphical representations of the risks of bias. </p> <div class="figure" id="CD003504-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003504-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003504-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003504-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003504-sec3-0021"> <h4 class="title">Allocation</h4> <p>Six studies were at low risk of bias for random sequence generation (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>). Two studies (<a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) were deemed to have an unclear risk of bias because of inadequate reporting. </p> <p>Five studies clearly demonstrated good allocation concealment (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>), whilst in the remaining three studies (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) the allocation concealment was not clearly described. </p> </section> <section id="CD003504-sec3-0022"> <h4 class="title">Blinding</h4> <p>Intravascular brachytherapy presents significant logistical hurdles, making bias difficult to prevent. In order to attempt at least one level of blinding, interpretation of results data ideally should be carried out by members of the team not involved in performing the interventional procedures. However, even this is open to bias as the participants would be aware of which treatment arm they were in. </p> <p>A sham brachytherapy procedure was performed in several trials in order to blind the participants to the therapy they were undergoing. The sham procedure was performed by placing a dummy wire intravascularly in place of the radioactive source. The following studies used a sham procedure: <a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>, <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> and <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>. The other four studies (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) did not include a sham procedure, which therefore introduced a high risk of bias. In <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> blinding was unclear as the study was not published and was only reported in a meeting. </p> <p>Three studies (<a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) were at unclear risk of detection bias because details of outcome assessment were not reported. In the remaining five studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) detection bias was judged to be at low risk because the clinical follow‐up or outcome assessments were performed blinded to the treatment groups. </p> </section> <section id="CD003504-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>In five studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) all participants were accounted for and there were no missing data. In the remaining three studies (<a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) some participants were lost to follow‐up with no information given on their status. </p> </section> <section id="CD003504-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>In the <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> study there was high risk of bias due to selective reporting as the study authors did not report their secondary outcome of class change according to the Rutherford scale, but instead reported on absence of claudication. Due to the lack of publication of the results of the <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> study it was unclear if there was any reporting bias. The remaining six studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) showed low risk of bias. </p> </section> <section id="CD003504-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>In three studies (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) there was a high risk of other potential sources of bias. </p> <p>The <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> trial used a 2 x 2 factorial design looking at IVBT and probucol. This introduced a potentially high risk of bias as it was not possible to independently compare the main effects of each of the four treatment arms. The study stopped early due to the significant effect on the primary endpoint and the treatment group received clopidogrel in addition to the treatment. </p> <p>The <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> study reported the per protocol analysis rather than an intention‐to‐treat (ITT) analysis with seven participants crossing from brachytherapy to the control group, which introduced a high risk of bias. </p> <p>The <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> trial introduced a high risk of bias with an inadequate number to give the study sufficient power, according to the trial report. </p> <p>In the <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> study other potential sources of bias were unclear as the study was not published and was only reported in a meeting. </p> <p>The remaining four studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) had a low risk of bias as there was no indication of other sources of bias. </p> </section> </section> <section id="CD003504-sec2-0010"> <h3 class="title" id="CD003504-sec2-0010">Effects of interventions</h3> <section id="CD003504-sec3-0026"> <h4 class="title">Primary outcomes</h4> <section id="CD003504-sec4-0003"> <h5 class="title">Primary patency or restenosis</h5> <section id="CD003504-sec5-0001"> <h6 class="title">Patency</h6> <p>Clinical patency is defined as sustained clinical success without further intervention, whilst cumulative patency is defined as the percentage of lesions which have &lt; 50% restenosis with or without further intervention during the follow‐up period. </p> <p>Clinical patency at six and 12 months was measured by only one trial (<a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) with no statistically significant differences between procedures (at six months: OR 0.79, 95% CI 0.31 to 1.99, n = 88; at 12 months: OR 1.36, 95% CI 0.58 to 3.20, n = 88) (<a href="./references#CD003504-fig-00101" title="">Analysis 1.1</a>). </p> <p>Cumulative patency was reported by two trials (<a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) and at 24 months showed an improved patency in participants receiving IVBT compared with no IVBT (OR 2.36, 95% CI 1.36 to 4.10, n = 222, I<sup>2</sup> = 35%) (<a href="./references#CD003504-fig-00102" title="">Analysis 1.2</a>). </p> <p>See <a href="#CD003504-tbl-0003">Table 2</a>. </p> <div class="table" id="CD003504-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of patency</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical patency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.31 to 1.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.58 to 3.20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative patency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (1.36 to 4.10)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </div> </section> <section id="CD003504-sec5-0002"> <h6 class="title">Restenosis</h6> <p>Restenosis is the narrowing of a blood vessel after it has been opened, usually by balloon angioplasty. It is defined as ≥ 50% luminal diameter stenosis. </p> <p>Restenosis at six months was measured in five studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>). The OR was 0.27 (95% CI 0.11 to 0.66, n = 562, I<sup>2</sup> = 75%) showing low restenosis for participants receiving IVBT compared with no IVBT. Similar results were found at 12 months (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) after the procedure (OR 0.44, 95% CI 0.28 to 0.68, n = 375, I<sup>2</sup> = 0%) and at 24 months (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) (OR 0.41, 95% CI 0.21 to 0.78, n = 164, I<sup>2</sup> = 0%). There was no statistically significant difference at 60 months (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) (OR 1.00, 95% CI 0.42 to 2.39, n = 102) (<a href="./references#CD003504-fig-00103" title="">Analysis 1.3</a>). </p> <p>See <a href="#CD003504-tbl-0004">Table 3</a>. </p> <div class="table" id="CD003504-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Restenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restenosis or reocclusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.11 to 0.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.28 to 0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.21 to 0.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.42 to 2.39)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </div> </section> </section> <section id="CD003504-sec4-0004"> <h5 class="title">Need for re‐intervention</h5> <p>The need for re‐intervention and revascularisation was well reported in the trials. Re‐intervention was indicated by symptomatic restenosis or reocclusions post‐intervention either in the treated segment (target lesion revascularisation) or secondary to progression of the disease in non‐treated segments of the vessel (target vessel revascularisation). This set of participants included those in whom the need for revascularisation may have been due to luminal stenosis secondary to the edge effect, that is at the edges of the irradiated area. </p> <section id="CD003504-sec5-0003"> <h6 class="title">Target lesion revascularisation (TLR)</h6> <p>TLR at six months was reported in three trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) and showed a statistical difference favouring IVBT (OR 0.51, 95% CI 0.27 to 0.97, n = 220, I<sup>2</sup> = 0%) (<a href="./references#CD003504-fig-00104" title="">Analysis 1.4</a>). </p> <p>TLR at 12 months was reported in three trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) and showed no statistical difference between groups (OR 0.44, 95% CI 0.19 to 1.02, n = 215, I<sup>2</sup> = 22%) (<a href="./references#CD003504-fig-00105" title="">Analysis 1.5</a>). </p> <p>TLR at 24 months was reported in one trial (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>) and showed no statistical difference between groups (OR 0.46, 95% CI 0.04 to 5.75, n = 30) (<a href="./references#CD003504-fig-00106" title="">Analysis 1.6</a>). </p> <p>TLR at 60 months was reported in one trial (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) and showed no statistical difference between groups (OR 0.92, 95% CI 0.41 to 2.06, n = 102) (<a href="./references#CD003504-fig-00107" title="">Analysis 1.7</a>). </p> <p>See <a href="#CD003504-tbl-0005">Table 4</a>. </p> <div class="table" id="CD003504-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Target lesion revascularisation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target lesion revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.27 to 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.19 to 1.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.04 to 5.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.41 to 2.06)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </div> </section> <section id="CD003504-sec5-0004"> <h6 class="title">Target vessel revascularisation (TVR)</h6> <p>TVR at six months was reported in three trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) and showed no statistical difference between groups (OR 0.55, 95% CI 0.30 to 1.01, n = 393, I<sup>2</sup> = 0%) (<a href="./references#CD003504-fig-00104" title="">Analysis 1.4</a>). </p> <p>TVR at 12 months was reported in two trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) and showed no statistical difference between groups (OR 5.43, 95% CI 0.61 to 48.25, n = 164, I<sup>2</sup> = 0%) (<a href="./references#CD003504-fig-00105" title="">Analysis 1.5</a>). </p> <p>TVR at 24 months was reported in one trial (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>) and showed no statistical difference between groups (OR 2.36, 95% CI 0.36 to 15.45, n = 30) (<a href="./references#CD003504-fig-00106" title="">Analysis 1.6</a>). </p> <p>TVR at 60 months was reported in one trial (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) and showed no statistical difference between groups (OR 0.91, 95% CI 0.38 to 2.15, n = 102) (<a href="./references#CD003504-fig-00107" title="">Analysis 1.7</a>). </p> <p>See <a href="#CD003504-tbl-0006">Table 5</a>. </p> <div class="table" id="CD003504-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Target vessel revascularisation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target vessel revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.30 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.43 (0.61 to 48.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (0.36 to 15.45)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.38 to 2.15)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </div> </section> <section id="CD003504-sec5-0005"> <h6 class="title">Need for re‐intervention</h6> <p>The need for re‐intervention not specifically identified as TLR or TVR was reported at 12 months in two trials (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) and showed no statistical difference between groups (OR 0.36, 95% CI 0.12 to 1.12, n = 234) (<a href="./references#CD003504-fig-00105" title="">Analysis 1.5</a>). </p> </section> </section> </section> <section id="CD003504-sec3-0027"> <h4 class="title">Secondary outcomes</h4> <section id="CD003504-sec4-0005"> <h5 class="title">Occlusions</h5> <p>Five studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) looked at occlusion rates and showed no statistical difference at several time points (no time given: OR 3.21, 95% CI 0.12 to 85.20, n = 30 (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>); at less than one month: OR 2.18, 95% CI 0.76 to 6.32, n = 275, I<sup>2</sup> = 0% (<a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>); and at 12 months: OR 0.84, 95% CI 0.13 to 5.27, n = 100 (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>)). Occlusions were statistically significantly fewer in the control group at more than three months (OR 11.46, 95% CI 1.44 to 90.96, n = 363, I<sup>2</sup> = 0%) (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) (<a href="./references#CD003504-fig-00108" title="">Analysis 1.8</a>). </p> </section> <section id="CD003504-sec4-0006"> <h5 class="title">Immediate success of procedure (within 30 days)</h5> <p>Several of the studies excluded participants in whom initial PTA failed or in whom the lesion length was outside of the trial parameters. These participants were not included in this analysis. Three trials reported 100% success of the procedure (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>). Five trials reported failures in the initial brachytherapy procedures (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>). </p> <p><a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a> reported that one participant undergoing IVBT developed a thromboembolic occlusion of a lower limb vessel during the procedure, which was immediately treated successfully with thrombolysis. In the <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> trial, the standard balloon angioplasty was successful in 89% to 91% of participants in each of the four participant groups, with 24 angioplasty failures (nine occlusions were not crossed; 15 participants failed the angiographic criteria for successful angioplasty) and two cases of an incorrectly placed applicator catheter. The initial phase of the <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> trial had a procedural success of 35 out of 40 interventions, but no further information was provided for the main trial. In the <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trial all initial PTA interventions were successful, but in the IVBT group they had seven technical failures: five due to a missed segment and two due to failure to advance the catheter. The <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> reported that two participants in the IVBT group had unsuccessful treatment due to kinking of the catheter preventing correct placement. </p> </section> <section id="CD003504-sec4-0007"> <h5 class="title">Limb loss or amputation free survival</h5> <p>One study (<a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) presented data for limb loss and showed no statistical difference between groups (OR 0.33, 95% CI 0.01 to 8.21, n = 134) (<a href="./references#CD003504-fig-00109" title="">Analysis 1.9</a>). </p> </section> <section id="CD003504-sec4-0008"> <h5 class="title">Cardiovascular death</h5> <p>The mortality data from three studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) were pooled and showed no statistical difference between the experimental and control groups (OR 2.69, 95% CI 0.39 to 18.40, n = 365, I<sup>2</sup> = 0%) (<a href="./references#CD003504-fig-00110" title="">Analysis 1.10</a>). </p> <p>The <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trial reported two cardiac deaths at nine months post‐intervention, but did not specify the treatment groups. Five participants died from coronary heart disease during the <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> trial, but the treatment groups were not specified. </p> </section> <section id="CD003504-sec4-0009"> <h5 class="title">Death from all causes</h5> <p>The mortality data from seven studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) were pooled and showed no statistical difference between the experimental and control groups (OR 0.89, 95% CI 0.42 to 1.87, n = 789, I<sup>2</sup> = 0%). No statistical significant difference was determined at any of the time points (<a href="./references#CD003504-fig-00111" title="">Analysis 1.11</a>). </p> <p><a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a> reported one death at 15 months from gastric bleeding in the brachytherapy (BT) group. </p> <p>There were three reported deaths in the <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> trial: two participants in the BT group died of myocardial infarction and one in the control group died of a ruptured abdominal aortic aneurysm. </p> <p>There were three deaths reported at 12 months in the <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trial: two from cardiac causes and one from an accident. </p> <p>The <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> trial reported two deaths: one from a myocardial infarction in the BT group and one due to cancer in the control group. </p> <p>Causes of death were not given in <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> (17 deaths) or <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> (one death). For the 12 month follow‐up in <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> there was one death in the control group after a recurrence in the segment treated with a stent. </p> <p>No details on deaths were available for the <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> trial. </p> </section> <section id="CD003504-sec4-0010"> <h5 class="title">Complications</h5> <p>The risk of complications was reported in six trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) and appeared to favour the control group (OR 2.02, 95% CI 0.90 to 4.52, n = 518, I<sup>2</sup> = 0%) (<a href="./references#CD003504-fig-00112" title="">Analysis 1.12</a>). </p> <p>One procedural occlusion was reported by <a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>. The <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trial reported that there were no complications. </p> <p>There were several complications reported in the <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> trial: two participants in the IVBT group required stenting due to severe dissections with partial luminal obstruction and one participant in the control group had acute thrombotic occlusion at 24 hours. Four participants had minor haematomas post‐procedure and one participant complained of neuropathic pain in the groin, which resolved in six weeks, but it was not reported which groups these five participants were in. </p> <p><a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> reported one pseudoaneurysm, one haematoma and five moderate treatment site arterial ectasia in the BT group, and one pseudoaneurysm, one haematoma and one moderate treatment site arterial ectasia in the control group. </p> <p><a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> reported 12 pseudoaneurysms, which were detected with routine post‐procedure ultrasound and successfully treated with ultrasound‐guided compression or thrombin injection, though they did not comment on which groups these participants were in. They did, however, report three acute thrombotic occlusions and two acute embolisations in the BT group, and two acute thrombotic occlusions in the control group. </p> <p>Minor procedural complications were reported in the <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> trial: four in the IVBT group (three pseudoaneurysms and one distal embolisation that required embolectomy) and five in the control group (three pseudoaneurysms, one minor bleeding, and one distal embolisation that required embolectomy). All pseudoaneurysms were successfully treated with ultrasound‐guided compression. The trialists also reported seven early thrombotic occlusions in the BT group and two in the control group. </p> <p>There was no reporting of complications in two trials (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>). </p> </section> <section id="CD003504-sec4-0011"> <h5 class="title">Bleeding</h5> <p>One trial (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) specified that there were no peri‐procedural bleeding complications in either group. The remaining studies did not assess or report bleeding outcomes. </p> </section> <section id="CD003504-sec4-0012"> <h5 class="title">Ankle brachial index (ABI)</h5> <p>ABI is the highest systolic pressure at the ankle compared to the highest of the right or left brachial systolic pressures and was reported by four studies. </p> <p>One study reported the ABI at 24 hours post‐intervention (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>) and one study reported the ABI at six months (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>), but these results were not significantly different between the treatment groups. However, at 12 months follow‐up one study (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) showed a statistically significant difference favouring the IVBT group (MD 0.08, 95% CI 0.02 to 0.14, n = 100, P = 0.02) (<a href="./references#CD003504-fig-00113" title="">Analysis 1.13</a>). </p> <p>Two more studies (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) reported ABI results. In the <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> study, the mean ABI was reported at 24 hours (control group: 0.79, range 0.40 to 1.13; IVBT: 0.85, range 0.48 to 1.09), at three months (control group: 0.77, range 0.15 to 1.14; IVBT: 0.88, range 0.47 to 1.20) and six months (control group: 0.74, range 0.21 to 1.25; IVBT: 0.84, range 0.27 to 1.25). <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> reported the ABI measurements as mean ± standard deviation per extremities at 24 hours (control group: 0.84 ± 0.22; IVBT: 0.87 ± 0.20; P = 0.55), at six months (control group: 0.74 ± 0.25; IVBT: 0.89 ± 0.23; P = 0.020) and at 12 months (control group: 0.71 ± 0.25; IVBT: 0.91 ± 0.20; P = 0.12). </p> </section> <section id="CD003504-sec4-0013"> <h5 class="title">Pain free walking distance</h5> <p>Only <a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a> reported results for walking distance at one month post‐intervention. No statistical difference between groups was shown (MD 20.40, 95% CI ‐117.41 to 158.21, n = 30) (<a href="./references#CD003504-fig-00114" title="">Analysis 1.14</a>). </p> </section> <section id="CD003504-sec4-0014"> <h5 class="title">Maximum walking distance on a treadmill</h5> <p>Two trials provided results for maximum walking distance on a treadmill with no statistically significant benefit for either group at one month (MD 23.40, 95% CI ‐101.03 to 147.83, n = 30) (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>), at six months (MD 92.00, 95% CI ‐62.71 to 246.71, n = 43) (<a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) or at 12 months (MD 55.00, 95% CI ‐130.65 to 240.65, n = 29) (<a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>) (<a href="./references#CD003504-fig-00115" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> stated that treadmill tests formed part of their clinical assessment of participants, but did not report these results in any of their publications. </p> </section> <section id="CD003504-sec4-0015"> <h5 class="title">Quality of life</h5> <p>One trial (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>) reported scores for quality of life self‐assessments, but the difference was not statistically significant for the two groups (MD 2.70, 95% CI ‐1.06 to 6.46, n = 30) (<a href="./references#CD003504-fig-00116" title="">Analysis 1.16</a>). </p> </section> <section id="CD003504-sec4-0016"> <h5 class="title">Other outcome measures</h5> <section id="CD003504-sec5-0006"> <h6 class="title">Cost‐effectiveness</h6> <p>A cost‐effectiveness analysis was considered, but no data were available in the included studies to perform such an analysis. </p> </section> <section id="CD003504-sec5-0007"> <h6 class="title">De novo restenosis</h6> <p>De novo restenosis was reported by trials at six months follow‐up (<a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) and appeared to favour the IVBT group (OR 0.39, 95% CI 0.20 to 0.78, n = 158) (<a href="./references#CD003504-fig-00117" title="">Analysis 1.17</a>). </p> </section> <section id="CD003504-sec5-0008"> <h6 class="title">Binary restenosis</h6> <p>Two studies (<a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) reported binary restenosis and showed a statistically significant difference in favour of the IVBT group (OR 0.57, 95% CI 0.20 to 1.67, n = 209, I<sup>2</sup> = 67%) (<a href="./references#CD003504-fig-00118" title="">Analysis 1.18</a>). </p> </section> <section id="CD003504-sec5-0009"> <h6 class="title">Peak velocity ratio</h6> <p>The peak velocity ratio of the stenosis is the ratio of peak systolic velocity within the stenosis to peak systolic velocity just prior to the stenosis. </p> <p>Three studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) reported the peak velocity ratios at different time points. No statistically significant difference was found between the experimental and control groups by two of the studies (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) immediately after the procedure (MD 0.12, 95% CI ‐0.06 to 0.29, n = 130, I<sup>2</sup> = 0%), by one study (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>) at 24 hours (MD ‐0.05, 95% CI ‐0.21 to 0.11, n = 275) or by one study (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) at 12 months (MD ‐1.16, 95% CI ‐0.40 to 0.08, n = 100). However, at six months data from two studies (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) showed a statistically significant difference in favour of the experimental group (MD ‐0.50, 95% CI ‐0.93 to ‐0.07, n = 375, I<sup>2</sup> = 58%) (<a href="./references#CD003504-fig-00119" title="">Analysis 1.19</a>). </p> <p>The peak velocity ratio was reported by three other studies (<a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>). <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> and <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> reported peak velocity ratio as the mean and range value, and did not include any statistical calculations. The values that were reported suggested that at six and 12 months the IVBT group was favoured as the values were lower than in the control group. The mean peak velocity ratio in the extremities was measured at 24 hours post‐intervention and at six and 12 months in one study (<a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>), which showed a statistically significant difference between groups, favouring the IVBT group (control group: 2.20 ± 1.20; IVBT: 1.56 ± 0.62; P = 0.03), only at the six months follow‐up. </p> </section> <section id="CD003504-sec5-0010"> <h6 class="title">Lumen area</h6> <p>Two studies (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) reported the lumen area at 24 hours and showed no statistically significant difference between the experimental and control groups (MD ‐1.10, 95% CI ‐3.52 to 1.32, n = 44). One study (<a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) reported the lumen area at six months and showed a statistically significant difference in favour of the IVBT group for an increase in the lumen area (MD 6.50, 95% CI 0.05 to 12.95, n = 24). One study (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>) reported the lumen area at 24 months and showed a statistically significant difference in favour of the IVBT for an increase in the lumen area (MD 7.30, 95% CI 4.67 to 9.93, n = 20, I<sup>2</sup> = 0%) (<a href="./references#CD003504-fig-00120" title="">Analysis 1.20</a>). </p> </section> <section id="CD003504-sec5-0011"> <h6 class="title">Vessel wall area</h6> <p>Two studies (<a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) provided data on vessel wall area at 24 hours, while one study (<a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>) included data at six and 24 months (<a href="./references#CD003504-fig-00121" title="">Analysis 1.21</a>). They showed no significant difference between the two groups (at 24 hours: MD ‐4.10, 95% CI ‐12.09 to 3.90, n = 44, I<sup>2</sup> = 51%; at six months: MD 6.40, 95% CI ‐4.16 to 16.96, n = 24; at 24 months: MD 2.70, 95% CI ‐3.89 to 9.29, n = 20). </p> </section> <section id="CD003504-sec5-0012"> <h6 class="title">Plaque area</h6> <p>Only the <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> study provided data on plaque area as determined by intravascular ultrasound at 24 hours and six months (<a href="./references#CD003504-fig-00122" title="">Analysis 1.22</a>). They showed no significant difference between the two groups (at 24 hours: MD ‐2.70,95% CI ‐8.82 to 3.42, n = 24; at six months: MD 2.40, 95% CI ‐4.25 to 9.05, n = 24). </p> </section> <section id="CD003504-sec5-0013"> <h6 class="title">Other</h6> <p><a href="./references#CD003504-bbs2-0079" title="SchillingerM , MlekuschW , WolframRM , BudinskyAC , ExnerM , RumpoldH , et al. Endovascular brachytherapy: effect on acute inflammatory response after percutaneous femoropopliteal arterial interventions. Radiology2004;230(2):556‐60. ">Schillinger 2004</a> took a subset of 47 participants sequentially recruited to the <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> (no stenting) and <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> (stenting) trials to assess the effect of PTA with and without stenting and with or without BT on the acute phase inflammatory response using C‐reactive protein (CRP), serum amyloid A (SAA) and fibrinogen levels as markers. Although they found a trend towards an enhanced response in those participants additionally treated with BT, this only achieved significance in participants undergoing BT and stenting at the 24 hour assessment (CRP: P = 0.02, SAA: P = 0.04, fibrinogen: P = 0.88), and was not sustained at 48 hours. However, the numbers of participants were very small (PTA + BT: n = 8, PTA alone: n = 7, PTA + stent + BT: n = 15, PTA + stent only: n = 17). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003504-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003504-sec1-0005"></div> <section id="CD003504-sec2-0011"> <h3 class="title" id="CD003504-sec2-0011">Summary of main results</h3> <p>A total of 1090 participants were included in the eight trials.</p> <p>In this review, patency or restenosis were reported in seven studies. Overall, a statistically significant benefit for IVBT was found for cumulative patency at 24 months (OR 2.36, 95% CI 1.36 to 4.10, n = 222). Clinical patency after six and 12 months was not statistically significantly different between the procedures as reported in one study. A statistically significant difference for IVBT was found for restenosis at six months (OR 0.35, 95% CI 0.24 to 0.50, n = 562), 12 months (OR 0.42, 95% CI 0.42 to 0.65; n = 375) and 24 months (OR 0.41, 95% CI 0.21 to 0.78; n = 164). No difference was found after 60 months as measured in one study. </p> <p>The need for re‐interventions was reported in six studies. Target lesion revascularisation was significantly reduced in trial participants treated with IVBT compared with angioplasty alone (OR 0.51, 95% CI 0.27 to 0.97, P = 0.04) at six months after the interventions. No statistically significant difference between the procedures was found for need for re‐intervention at 12 and 24 months after the procedures. </p> <p>Occlusions were statistically significantly fewer in the control group at more than three months (OR 11.46, 95% CI 1.44 to 90.96, n = 363), but no differences were found after less than one month or 12 months after the procedures. </p> <p>Limb loss was reported in one trial and showed no statistically significant difference between procedures. </p> <p>The number of cardiovascular deaths was reported in three studies and showed no statistically significant difference between procedures. </p> <p>Death from all causes was reported by seven trials at six different time intervals, ranging from six to 60 months, with no statistically significant difference found between interventions. </p> <p>Complications were reported by seven trials with no statistically significant difference between the interventions. </p> <p>ABI was reported in two studies and was statistically significant for IVBT only at the 12 month follow‐up (MD 0.08, 95% CI 0.02 to 0.14, n = 100). No differences were found between the treatments at the 24 hour and six month intervals. </p> <p>Pain free walking distance, maximum walking distance on a treadmill and quality of life were similar for the two arms of the trials with no statistically significant difference found between the procedures. </p> <p>Cost‐effectiveness was not assessed in any of the included studies.</p> </section> <section id="CD003504-sec2-0012"> <h3 class="title" id="CD003504-sec2-0012">Overall completeness and applicability of evidence</h3> <p>Overall, the benefits of brachytherapy following angioplasty over conventional angioplasty are limited. Use of brachytherapy may be recommended for a medium‐term one year reduction in restenosis rate. As the included studies have a variety of outcomes, and time intervals for the outcomes, potentially the data do not represent the whole picture for using brachytherapy for PAD. </p> <p>The literature search identified only RCTs using the femoropopliteal artery. We did not identify RCTs using the iliac arteries, therefore the available evidence cannot be interpreted for arteries other than the femoropopliteal artery. </p> <p>All included studies compared PTA with and without stenting plus IVBT with PTA with and without stenting alone. No trials were found comparing IVBT to newer technologies such as drug eluting stents, balloons, or cryoplasty. </p> <p>The very long‐term outcomes (more than 10 years) remain unknown as no data beyond 60 months was identified. However, this may in some respects not be so relevant because of the low survival rate after five years as shown in <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>. </p> <p>As well as clinical effectiveness, cost‐effectiveness and quality of life will need to be evaluated before brachytherapy can be recommended for widespread use. Limited or no information is available for these outcomes. </p> <p>Since the publication of the first version of this review, and indeed the publication of many of the included studies, the outcome measures deemed relevant to the success of peripheral vascular interventions have evolved from patency and stenosis to number of re‐interventions and quality of life. We have reordered the outcomes of this review update to reflect the importance of the outcomes and current practice. However, we are unable to change the outcomes as reported by the published studies. It is possible that this change in importance of outcome measures over time has affected the findings of this review. </p> </section> <section id="CD003504-sec2-0013"> <h3 class="title" id="CD003504-sec2-0013">Quality of the evidence</h3> <p>The quality of the included trials was moderate, with our concerns relating to the difficulty of blinding due to the nature of the procedures and the small sample sizes for some studies. Primary outcomes (patency or restenosis and need for re‐intervention) were reported in the majority of the trials, but reporting at various time points and the use of multiple definitions of the outcomes by the included studies meant that not all data were available for pooling. The secondary outcomes were not reported in many of the included studies. </p> <p>The review included trials where brachytherapy was an adjunct to the treatment of participants with PAD or stenosed bypass grafts versus procedures without brachytherapy. The eight included studies involved a total of 1090 participants with PAD who required vascular intervention that could be appropriately managed by IVBT and who were deemed fit to undergo such an intervention. Some of the included studies incorporated small samples and this should be considered when interpreting the findings. The effect estimates for the primary outcomes (primary patency or restenosis, or need for re‐intervention at various time points) produced narrow 95% confidence intervals. Together with the absence of heterogeneity between trials these suggest that the findings are robust. However, for the outcomes restenosis at six months, binary restenosis, peak velocity at six months and vessel wall area at 24 hours, where the heterogeneity was more than 50%, the findings should be interpreted with caution. </p> </section> <section id="CD003504-sec2-0014"> <h3 class="title" id="CD003504-sec2-0014">Potential biases in the review process</h3> <p>The methods used to conduct the review are described in detail in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003504-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic reviews of Interventions Version 5.1.0 [updated March 2011]. Wiley‐Blackwell, 2011. ">Higgins 2011</a>). Particular strengths are the independent application of the review eligibility criteria, independent data extraction, and assessment of the risk of bias. Two authors (AA, MS) independently extracted the data. We attempted to identify all relevant studies. Further data and information were obtained for specific outcomes of this review. The studies used individual participants as the unit of analysis. </p> </section> <section id="CD003504-sec2-0015"> <h3 class="title" id="CD003504-sec2-0015">Agreements and disagreements with other studies or reviews</h3> <p>There are several reviews that evaluated the use of brachytherapy as an adjuvant in people with PAD undergoing angioplasty procedures. </p> <p>A review of the Vienna (<a href="./references#CD003504-bbs2-0019" title="MinarE , PokrajacB , AhmadiR , MacaT , SeitzW , StumpflenA , et al. Brachytherapy for prophylaxis of restenosis after long‐segment femoropopliteal angioplasty: pilot study. Radiology1998;208(1):173‐9. ">Vienna 1</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>; <a href="./references#CD003504-bbs2-0020" title="WolframRM , PokrajacB , AhmadiR , FellnerC , GyongyosiM , HaumerM , et al. Endovascular brachytherapy for prophylaxis against restenosis after long‐segment femoropopliteal placement of stents: initial results. Radiology2001;220(3):724‐9. ">Vienna 4</a>; <a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a>), Frankfurt (<a href="./references#CD003504-bbs2-0012" title="LiermannD , KirchnerJ , BauernsachsR , SchopohlB , BottcherHD . Brachytherapy with iridium‐192 HDR to prevent from restenosis in peripheral arteries. An update. Herz1998;23(6):394‐400. ">Liermann 1998</a>), PARIS (<a href="./references#CD003504-bbs2-0015" title="WaksmanR , LairdJR , JurkovitzCT , LanskyAJ , GerritsF , KosinskiAS , et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. Journal of Vascular and Interventional Radiology2001;12(8):915‐21. ">PARIS I</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>) and Bern (<a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) studies concluded that brachytherapy is feasible and effective but could not give brachytherapy a definite role in the prophylaxis of restenosis (<a href="./references#CD003504-bbs2-0071" title="PokrajacB , MinarE , KirisitsC , PotterR . Present status of endovascular brachytherapy in peripheral arteries. Herz2002;27(1):56‐61. ">Pokrajac 2002b</a>), a result that was similar to our review for long‐term restenosis rates. </p> <p>The use of peripheral artery brachytherapy as an adjunct to PTA for the prevention of restenosis in the femoropopliteal system did provide improved health outcomes in a review of two trials (<a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>) but the study authors did not have enough evidence for the role of brachytherapy for the prevention of restenosis (<a href="./references#CD003504-bbs2-0086" title="Technology Evaluation Center. Brachytherapy for the prevention of restenosis in peripheral arteries following PTA of the femoropopliteal system. Technology evaluation center assessment program2003;17(22):1‐17. ">Technology 2003</a>). </p> <p><a href="./references#CD003504-bbs2-0044" title="GorenoiV , DintsiosCM , SchönermarkMP , HagenA . Intravascular brachytherapy for peripheral arterial occlusive disease: systematic review of medical efficacy and health economic modelling [Intravaskuläre Brachytherapie bei peripherer arterieller Verschlusskrankheit: Systematische Übersicht zur medizinischen Wirksamkeit und gesundheitsökonomische Modellierung]. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen2009;103(6):331‐40. ">Gorenoi 2009</a> reviewed intravascular brachytherapy (IVBT) in people with peripheral arterial occlusive disease and found that the use of brachytherapy after successful balloon dilatation showed a significant reduction in the rate of restenosis at six and 12 months (OR 0.62, 95% CI 0.46 to 0.84) and a significant delay in the time to recurrence of restenosis (17.5 versus 7.4 months, P &lt; 0.01). The low restenosis result is similar to the low restenosis at six and 12 months in this systematic review. <a href="./references#CD003504-bbs2-0044" title="GorenoiV , DintsiosCM , SchönermarkMP , HagenA . Intravascular brachytherapy for peripheral arterial occlusive disease: systematic review of medical efficacy and health economic modelling [Intravaskuläre Brachytherapie bei peripherer arterieller Verschlusskrankheit: Systematische Übersicht zur medizinischen Wirksamkeit und gesundheitsökonomische Modellierung]. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen2009;103(6):331‐40. ">Gorenoi 2009</a> also showed an estimated additional cost of approximately EUR 1700 for brachytherapy to be used as an adjuvant to other treatments such as balloon dilatation, PTA with an optional stent, or after stenting. </p> <p>A systematic review and meta‐analysis of endovascular brachytherapy looked at restenosis following lower limb angioplasty (<a href="./references#CD003504-bbs2-0065" title="MitchellD , O'CallaghanAP , BoyleEM , KavanaghEG , WalshSR . Endovascular brachytherapy and restenosis following lower limb angioplasty: Systematic review and meta‐analysis of randomized clinical trials. International Journal of Surgery2012;10(3):124‐8. ">Mitchell 2012</a>). The review included six trials, three of which (<a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) were included in our current systematic review with the same name while two other trials were included under different names (Cologne: <a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a>; Bern: <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a>) and one was an update on a trial (Paris: <a href="./references#CD003504-bbs2-0015" title="WaksmanR , LairdJR , JurkovitzCT , LanskyAJ , GerritsF , KosinskiAS , et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. Journal of Vascular and Interventional Radiology2001;12(8):915‐21. ">PARIS I</a>; <a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a>). The authors concluded that endovascular brachytherapy cannot be recommended for routine clinical use because it has an increased risk of new lesions and it lacks a reduction in medium to long‐term risk of restenosis. Our review determined that at 60 months there was no benefit when using brachytherapy in term of restenosis rate. </p> <p>Interestingly, the use brachytherapy may increase in the future if beta‐emitting sources become more widely available (<a href="./references#CD003504-bbs2-0062" title="MinarE . Resuscitation of endovascular brachytherapy owing to improved logistics. Journal of Endovascular Therapy2012;19(4):476‐9. ">Minar 2012</a>). Using beta‐emitting sources would improve logistics and have technical advantages. An open, non‐randomised Limb Ischaemia Treatment and Monitoring post Vascular Brachytherapy to Prevent Restenosis (<a href="./references#CD003504-bbs2-0013" title="Novoste . The LIMBER trial (Limb ischemia treatment and monitoring post vascular brachytherapy to prevent restenosis). ">LIMBER</a>) trial was halted after recruiting 25 participants, with no results published. The <a href="./references#CD003504-bbs2-0014" title="Novoste . Corona system. Patient guide and information leaflet. http://www.bestvascular.com/assets/Beta‐Cath%203.5F%20%205F%20Systems%20Dose%20Equivalency.pdf (accessed 22 May 2013). ">MOBILE</a> (More Patency with Beta for In‐stent Restenosis in the Lower Extremity) trial, the only RCT for femoropopliteal brachytherapy using a beta source, was also halted by the company running it (Novoste) for financial reasons. The low penetration of beta‐radiation would require exact centring of the source within the lumen, however the radiation dose to the vessel wall could be more accurately determined. The Vienna group have published an initial feasibility study using the beta source strontium‐90 in a CO<sub>2</sub>‐filled centring catheter to deliver 14 to 18 Gy to recurrent stenoses or in‐stent stenoses of the SFA with some success (<a href="./references#CD003504-bbs2-0072" title="PokrajacB , KirisitsC , SchmidR , SchillingerM , BergerD , PeerK , et al. Beta endovascular brachytherapy using CO2‐filled centering catheter for treatment of recurrent superficial femoropopliteal artery disease. Cardiovascular Revascularization Medicine2009;10(3):162‐5. ">Pokrajac 2009a</a>). They reported 100% success for the procedure with no major adverse events and restenosis rates at one, two and three years of 9%, 28% and 40%. A RCT is urgently needed to explore this initial success further. </p> <p>A systematic review and meta‐analysis of additional technologies to enhance angioplasty for infrainguinal PAD looked at restenosis and the need for intervention as outcomes (<a href="./references#CD003504-bbs2-0083" title="SimpsonEL , MichaelsJA , ThomasSM , CantrellAJ . Systematic review and meta‐analysis of additional technologies to enhance angioplasty for infrainguinal peripheral arterial occlusive disease. British Journal of Surgery2013;100(9):1128‐37. ">Simpson 2013</a>). This review included four studies which looked at brachytherapy (<a href="./references#CD003504-bbs2-0037" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ">Diehm 2005</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>) as an additional technology to angioplasty. Of these four studies, <a href="./references#CD003504-bbs2-0037" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ">Diehm 2005</a> was a pooled subanalysis from the <a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> and <a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> trials. When compared with PTA alone, IVBT had a significant effect with low restenosis rates at 12 months as shown by three studies (<a href="./references#CD003504-bbs2-0037" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ">Diehm 2005</a>; <a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a>), but no significant effect at six months when two studies were considered (<a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a>; <a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003504-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003504-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003504-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003504-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 1 Clinical patency." data-id="CD003504-fig-00101" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 1 Clinical patency.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 2 Cumulative patency." data-id="CD003504-fig-00102" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 2 Cumulative patency.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 3 Restenosis." data-id="CD003504-fig-00103" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 3 Restenosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 4 Need for re‐intervention at 6 months." data-id="CD003504-fig-00104" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 4 Need for re‐intervention at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 5 Need for re‐intervention at 12 months." data-id="CD003504-fig-00105" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 5 Need for re‐intervention at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 6 Need for re‐intervention at 24 months." data-id="CD003504-fig-00106" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 6 Need for re‐intervention at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 7 Need for re‐intervention at 60 months." data-id="CD003504-fig-00107" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 7 Need for re‐intervention at 60 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 8 Occlusion." data-id="CD003504-fig-00108" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 8 Occlusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 9 Limb loss." data-id="CD003504-fig-00109" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 9 Limb loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 10 Cardiovascular death." data-id="CD003504-fig-00110" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 10 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 11 Death from all causes." data-id="CD003504-fig-00111" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 11 Death from all causes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 12 Complications." data-id="CD003504-fig-00112" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 12 Complications.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 13 ABI." data-id="CD003504-fig-00113" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 13 ABI.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 14 Pain free walking distance." data-id="CD003504-fig-00114" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 14 Pain free walking distance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 15 Maximum walking distance." data-id="CD003504-fig-00115" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 15 Maximum walking distance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 16 Quality of life (scores)." data-id="CD003504-fig-00116" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 16 Quality of life (scores).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 17 De novo restenosis." data-id="CD003504-fig-00117" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 17 De novo restenosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 18 Binary restenosis." data-id="CD003504-fig-00118" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 18 Binary restenosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 19 Peak velocity ratio." data-id="CD003504-fig-00119" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 19 Peak velocity ratio.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 20 Lumen." data-id="CD003504-fig-00120" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 20 Lumen.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 21 Vessel wall area." data-id="CD003504-fig-00121" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 21 Vessel wall area.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003504-fig-00122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/urn:x-wiley:14651858:media:CD003504:CD003504-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_t/tCD003504-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Brachytherapy versus no brachytherapy, Outcome 22 Plaque area." data-id="CD003504-fig-00122" src="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Brachytherapy versus no brachytherapy, Outcome 22 Plaque area.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-fig-00122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/media/CDSR/CD003504/image_n/nCD003504-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD003504-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exclusions/</p> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Complications</p> <p>(documented)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age (y)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> <p>(n)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean lesion length ‐</p> <p>control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean lesion length ‐</p> <p>treated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0001" title="KruegerK , LandwehrP , BendelM , NolteM , StuetzerH , BongartzR , et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology2002;224(2):519‐28. KruegerK , ZaehringerM , BendelM , StuetzerH , StroheD , NolteM , et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty ‐ angiographic and clinical follow‐up in a prospective randomized controlled trial. Radiology2004;231(2):546‐54. ">Krueger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (51 ‐ 73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0002" title="BonviniR , BaumgartnerI , DoDD , AlerciM , SegattoJM , TuttaP , et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. Journal of the American College of Cardiology2003;41(3):409‐12. DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. GallinoA , DoDD , AlerciM , BaumgartnerI , CozziL , SegattoJM , et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. Journal of Endovascular Therapy2004;11(6):595‐604. WyttenbachR , CortiR , AlerciM , CozziL , DiValentinoM , SegattoJM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow‐up by noninvasive magnetic resonance imaging. European Journal of Vascular and Endovascular Surgery2007;34(4):416‐23. WyttenbachR , GallinoA , AlerciM , MahlerF , CozziL , DiValentinoM , et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation2004;110(9):1156‐61. ">PAB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 ± 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0003" title="SchillingerM , MinarE . Advances in vascular brachytherapy over the last 10 years: Focus on femoropopliteal applications. Journal of Endovascular Therapy2004;11 Suppl 1:II180‐91. WaksmanR . Result of the PARIS trial. Annual Transcatheter Cardiovascular Therapeutics meeting. Washington DC, September 2003. ">PARIS II</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unpublished</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0004" title="DiehmN , SilvestroA , DoDD , GreinerR , TrillerJ , MahlerF , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. Journal of Endovascular Therapy2005;12(6):723‐30. ZehnderT , vonBrielC , BaumgartnerI , TrillerJ , GreinerR , MahlerF , et al. Endovascular brachytherapy after percutaneous transluminal angioplasty of recurrent femoropopliteal obstructions. Journal of Endovascular Therapy2003;10(2):304‐11. ">Swiss</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71 (45 ‐ 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0005" title="HagenaarsT , ApoIF , VanSambeekMR , CoenVL , VanTongerenRB , GescherFM , et al. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. Journal of Vascular Surgery2002;36(2):318‐24. VanTongerenRB , VanSambeekMR , vanOverhagenH , CoenVL , SchmitzPI , GescherFM , et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. Journal of Cardiovascular Surgery2005;46(4):437‐43. ">VARA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 + 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 (43 ‐ 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0006" title="MinarE , PokrajacB , MacaT , AhmadiR , FellnerC , MittlbockM , et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694‐9. PokrajacB , MinarE , MacaT , KnockeTH , FellnerC , AhmadiR , et al. Intraarterial 192Ir HDR BT for prophylaxis of restenosis after femoropopliteal transluminal angioplasty; prospective; randomised trial ‐ Vienna 2; results after 6 months minimum follow‐up; risk factor analysis. International Journal of Radiation Oncology, Biology, Physics1999;45(3):181 Abstract 67. PokrajacB , PotterR , MacaT , FellnerC , MittlbockM , AhmadiR , et al. Intraarterial (192)Ir high‐dose‐rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna‐2‐trial radiotherapy parameters and risk factors analysis. International Journal of Radiation Oncology, Biology, Physics2000;48(4):923‐31. PokrajacB , SchmidR , KirisitsC , MockU , FellnerC , WambersieA , et al. Possible impact of iridium‐192 source centering on restenosis rate after femoro‐popliteal angioplasty and endovascular brachytherapy in Vienna‐2 study. Radiotherapy and Oncology2002;63(1):97‐102. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: five‐year follow‐up‐‐prospective randomized study. Radiology2006;240(3):878‐84. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. WolframRM , PokrajacB , BudinskyAC , PotterR , MinarE . Five year to follow‐up after endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Circulation2004;110(III):647 belongs to Vienna 2 paper and not Vienna 3 as listed in abstract as numbers and radiation dose reflect those of Vienna 2 ‐ data not used in this review though. ">Vienna 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71 (43 ‐ 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0007" title="HofmannWJ , KoppM , KoflerB , UgurluogluA , KogelnikD , MagometschniggH . Preliminary observations on the need for control angiography after peripheral endovascular brachytherapy using a centering balloon. Journal of Endovascular Therapy2002;9(2):241‐5. PokrajacB , PotterR , WolframRM , BudinskyAC , KirisitsC , LilegB , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 randomised multicenter study. Radiotherapy and Oncology2005;74(1):3‐9. PokrajacB , SchmidR , PoetterR , WolframR , KirisitsC , KoppM , et al. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna‐3 multicenter study. International Journal of Radiation Oncology, Biology, Physics2003; Vol. 57, issue 2, Suppl:S250. WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery‐‐the Vienna experience. Radiology2005;236(1):338‐42. ">Vienna 3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003504-bbs2-0008" title="WolframRM , BudinskyAC , PokrajacB , PotterR , MinarE . Vascular brachytherapy with 192Iridium after femoropopliteal stent implantation in high‐risk patients: twelve‐month follow‐up results from the Vienna‐5 trial. Radiology2005;236(1):343‐51. ">Vienna 5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (50 ‐ 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>y: years<br/> n: number </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003504-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of patency</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical patency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.31 to 1.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (0.58 to 3.20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative patency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (1.36 to 4.10)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of patency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003504-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Restenosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restenosis or reocclusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27 (0.11 to 0.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.28 to 0.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.21 to 0.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.42 to 2.39)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Restenosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003504-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Target lesion revascularisation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target lesion revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.27 to 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.19 to 1.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.04 to 5.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.41 to 2.06)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Target lesion revascularisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003504-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Target vessel revascularisation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target vessel revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR (95% CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.30 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.43 (0.61 to 48.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (0.36 to 15.45)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.38 to 2.15)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: confidence interval<br/> N: number<br/> OR: odds ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Target vessel revascularisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/full#CD003504-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003504-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Brachytherapy versus no brachytherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical patency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.31, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.58, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cumulative patency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.36, 4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.36, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Restenosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.11, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.28, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.21, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.42, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for re‐intervention at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Target lesion revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.27, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Target vessel revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.30, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for re‐intervention at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Target lesion revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.19, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Target vessel revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.43 [0.61, 48.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Need for re‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for re‐intervention at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Target lesion revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Target vessel revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Need for re‐intervention at 60 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Target lesion revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Target vessel revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Occlusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 No time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.12, 85.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Less than 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.76, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 More than 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.46 [1.44, 90.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.13, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Limb loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.39, 18.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Death from all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.42, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 no time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.20, 24.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.12, 76.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.09, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 15 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.12, 85.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.23, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.90, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 ABI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Pain free walking distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 1 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Maximum walking distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 1 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Quality of life (scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 De novo restenosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.20, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.20, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Binary restenosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Peak velocity ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Immediately after procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.06, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.21, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.93, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.40, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Lumen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐3.52, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.50 [0.05, 12.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.30 [4.67, 9.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Vessel wall area <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.10 [‐12.09, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐4.16, 16.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐3.89, 9.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Plaque area <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Brachytherapy versus no brachytherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003504.pub2/references#CD003504-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003504.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003504-note-1210">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003504-note-1208">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003504-note-1209">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003504-note-1207">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003504-note-1206">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003504\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003504\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003504\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003504\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003504\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003504.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003504.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003504.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003504.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003504.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725605720"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003504.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725605724"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003504.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7f515f6bf466',t:'MTc0MDcyNTYwNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 